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Abstract: Hepatocellular carcinoma (HCC) is a relevant cause of cancer-
related mortality worldwide. Around half of HCC patients will receive 
systemic therapies during their life span. The pivotal positive sorafenib 
trial and regulatory approval in 2007 was followed by a decade of 
negative studies with drugs leading to marginal anti-tumoral efficacy, 
toxicity, or trials with lack of enrichment strategies. This trend has 
changed during the period 2016-18, when several compounds such as 
lenvatinib (in first line) and regorafenib, cabozantinib, ramucirumab and 
nivolumab (in second-line) showed clinical benefit. These successes came 
at a cost of increasing the complexity of decision-making, and 
ultimately, impacting the design of future clinical trials. Nowadays, 
life expectancy with single active agents has surpassed the threshold of 
1 year and the field is facing encouraging outcomes ~2 years with 
sequential strategies. Overall survival (OS) remains as the main endpoint 
in phase III investigations, but as in other solid tumors, there is a 
clear need to define surrogate endpoints that both reliably recapitulate 
survival benefits and can be assessed prior additional efficacious drugs 
are administered. A thorough analysis of 21 phase III trials published in 
advanced HCC demonstrated a moderate correlation between progression-free 
survival (PFS) or time to progression (TTP) with OS (R=0.84 and R=0.83, 
respectively). Nonetheless, significant differences in PFS were only 
followed by differences in survival in 3 out of 7 phase III studies. In 
these later cases, the magnitude of benefit for PFS was HR ≤ 0.6, and 
thus this threshold is herein proposed as a potential surrogate endpoint 
of OS in advanced HCC. Conversely, PFS with a HR between 0.6-0.7, despite 
significant, was not associated with better survival, and thus these 
magnitudes are considered uncertain surrogates. In the current review, we 
discuss the reasons for positive or negative phase III trials in advanced 
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HCC, and the strengths and limitations of clinical surrogate endpoints 
(PFS, TTP and objective response rate [ORR]) to predict survival. 
 
Response to Reviewers: Please see attached file 
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Barcelona, December 19th, 2018 
 
To:              Dr. Rajiv Jalan, Editor-in-Chief, Journal of Hepatology 
   Dr. Jessica Zucman-Rossi, Co-Editor, Journal of Hepatology 
   Dr. Jean-Charles Nault, Associate Editor, Journal of Hepatology 
 
Dear Editors,  
Thank you for considering our manuscript JHEPAT-D-18-01385R2, entitled: "Randomized trials 
and endpoints in advanced HCC: Role of PFS as a surrogate of survival” by Llovet JM et al. 
for further evaluation in order to be published in Journal of Hepatology.  
We have modified the manuscript to address some of the reviewers’ concerns/suggestions, 
including additional analyses following their recommendations in order to further strengthen the 
information obtained with the meta-analysis of phase III clinical trials conducted in advanced HCC.  
In the document enclosed, we describe the point-by-point response with changes to the manuscript 
text underlined to assist reviewers and include a clean final document. We hope that you will find 
the revised manuscript finally acceptable for publication in your prestigious Journal. 
 
Sincerely,  
 
 
 
 
 
 
 
 
 
  Josep M Llovet, MD 
 
Detailed Response to Reviewers
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POINT-BY-POINT RESPONSE (JHEPAT-D-18-01385R2) 
 
Dear Editors and Reviewers, 
We appreciate your comments on our manuscript. In the version enclosed we have addressed 
the points requested by reviewers and are positive that the revised version including your input 
has improved the overall message of the manuscript. Please, find below our point-by-point 
responses to the comments. In order to assist reviewers, we have established four writing 
modes in this document: black-bold for the original reviewer’s comment as included in the 
decision letter, black-regular for our responses to reviewer’s comments, italic for sentences 
that were already present in the manuscript and underlined for changes made to the original 
version. References already cited in the manuscript or added to the revised manuscript are 
numbered as per the new version of the manuscript.  
 
Reviewer #1:  
Despite being requested at all stages in the review process by both reviewers and the 
editor, the authors have chosen not to address the key issue of the SHAPRP and AP data. 
Their exclusion is not even mentioned as a limitation. According the extraordinary 
correlation between TTP and PFS it can be inferred that the HR for PFS was between 0.5 
and 0.7 for both trials yet both trials were positive. So you have 3 trials positive with HR 
<0.5 and 2 with HR > 0.5. This undermines the reliability of 0.5 threshold even before one 
considers the many other well-reported confounders of the relationship between PFS and 
OS. 
We thank again Reviewer #1 for this thoughtful observation. We agree that including PFS data 
for SHARP and AP trials in the meta-analysis would be ideal. However, we do not have access 
to the individual patient data of these trials [7-8] and thus cannot be included it in the manuscript. 
Despite the role of Dr. Llovet as co-PI in the SHARP clinical trial, he does not have access to 
the individual patient data, owned by the sponsor of the trial. Analysis of individual data to 
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explore the actual PFS of both trails will require an agreement with the sponsor beyond the 
scope of this review. Nonetheless, we are aware of the importance of the point highlighted by 
the reviewed and have now tried to address it in an indirect way by providing an estimation of  
the PFS. In order to estimate PFS in these 2 trials we took advantage of the high trial-level 
correlation observed between TTP and PFS in advanced HCC (Figure 4). According to the linear 
equation obtained comparing both surrogate endpoints [log HRPFS = 0.014 + 0.927 x log HRTTP], 
the inferred PFS HR of SHARP and AP trials are close to 0.60. Therefore, we have amended 
our 0.5 threshold for PFS, which certainly can be too stringent and have modified the proposed 
minimum threshold effect of PFS to 0.6. With this change, we are decreasing the positive 
predictive value of PFS to predict significant differences in OS, but certainly are capturing the 
trials for which PFS will be borderline and are certainly associated with a magnitude of clinical 
benefit in terms of OS. Slightly beyond that threshold of =0.6, we have examples of RCT that 
were positive for PFS but negative for OS (REACH HR-PFS=0.63 and HR-OS=0.87 and EACH 
HR-PFS=0.62; HR-OS=0.80). As a result of these changes we have modified the threshold in 
Fig 3, incorporating the estimated PFS of SHARP and Asian – Pacific trials.  
During this period of time, two recent studies have been released supporting our threshold of 
HR ≤ 0.6 for PFS, and thus we have included in the current submission. The first one, an 
individual-patient data meta-analysis of two randomized clinical trials (REACH[21] and REACH-
2[25]), showing a significant OS HR with a PFS HR of 0.57 (Llovet et al, Hepatology 2018; 68, 
AASLD 2018 meeting abstract). The second one, a phase 3 randomized clinical trial comparing 
sorafenib with or without cTACE in advanced HCC, a negative study for its primary endpoint 
(OS) with a PFS HR of 0.73 (JW Park et al, Journal of Hepatology 2018; in Press). 
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Figure 3: Correlation between surrogate endpoints (PFS[A] and TTP[B]) and hard endpoint (OS).  
Trial-level correlation between endpoints using criteria from the Institute for Quality and Efficiency in Health Care 
(IQWIG). R and R2 refers to the weighted Pearson coefficient between the HR of OS and the HR of the surrogate 
endpoint. IQWIG categorizes the strength of the correlation based on the value of R as low (R<0.7), moderate (R>0.7 
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to R<0.85) and high (R>0.85)[85]. Each dot represents one of the phase III clinical trials conducted on advanced 
HCC. Size of the dot is proportional to the total number of patients enrolled in the trial. Trials are colored based on 
whether the final result was positive, negative or non-inferior. X and Y axis depict the value of the HR for the surrogate 
(TTP or PFS) and the hard endpoint (OS), respectively. 
In summary, the changes in the text have been as follows:  
 
[Page 2, line 28]: In these later cases, the magnitude of benefit for PFS was HR ≤ 0.6, and thus 
this threshold is herein proposed as a potential surrogate endpoint of OS in advanced HCC. 
Conversely, PFS with a HR between 0.6-0.7, despite significant, was not associated with better 
survival, and thus these magnitudes are considered uncertain surrogates. 
 
[Page 4, line 38]: Based on this analysis and a conservative approach to define surrogates of 
OS in HCC, we propose PFS with a threshold of HR≤ 0.6 as reliable surrogate with solid positive 
predictive value, whereas the threshold of HR=0.6-0.7 -despite leading to positive statistical 
results- is defined as clinically uncertain in terms of capturing true advantages in OS. 
 
[Page 12, line 5]: When specifically analyzing the positive predictive value of theoretical 
thresholds of PFS correlating with OS, only 3/7 PFS reported a HR ≤0.6 that was significantly 
associated with a positive survival clinical benefit (in all cases with a HR for OS < 0.8). 
Conversely, those four studies reporting a positive PFS with a HR between 0.6-0.8 were 
associated with no significant survival benefits (HR for OS between 0.87 and 1.05) (Figure 3A). 
In our study, according to the linear regression equation obtained [log HROS = 0.072 + 0.487 x 
log HRPFS], a threshold of PFS HR=0.6 (representing a 40% risk reduction) will decrease ~17% 
the risk of OS (OS HR=0.83) (see Figure 3A). In summary, a moderate correlation has been 
established between PFS and OS in 21 RCTS in advanced HCC. A value of HR ≤0.6 is proposed 
as surrogate threshold effect [89], and is likely to predict a clinically meaningful improvement in 
OS. 
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[Page 13, line 13]: In fact, when we inferred the non-reported PFS HR of SHARP and AP trials 
according to the linear equation obtained comparing both surrogate endpoints [log HRPFS = 
0.014 + 0.927 x log HRTTP], the HR values are close to 0.60, just at the previously proposed 
minimum threshold. 
 
[Page 15, line 48]: In this scenario, PFS has shown moderate correlation with OS (R=0.84), and 
a threshold of HR≤0.6 defines a conservative approach of surrogate endpoint able to capture 
survival differences in a superiority trial with a high positive predictive value. Two recent studies 
have been released supporting our threshold of HR ≤ 0.6 for PFS. The first one, an individual-
patient data meta-analysis of two RCTs (REACH[21] and REACH-2[25], showing a significant 
OS HR with a PFS HR of 0.57[129]. The second one, a phase 3 RCT comparing sorafenib with 
or without cTACE in advanced HCC, a negative study for its primary endpoint (OS) with a PFS 
HR of 0.73[130].  Thus, PFS-HR ≤0.6 can be considered a candidate endpoint in phase II and 
phase III RCTs when subsequent therapies are expected to impact overall outcome. 
 
[Page 16, line 24]: PFS has a moderate correlation at trial level with OS (R=0.84). A conservative 
minimum surrogate threshold effect of HR ≤0.6 is highly predictive of a significant improvement 
in OS, whereas HR ranging from 0.6 – 0.7 are uncertain surrogates. 
 
[129] Llovet JM, Kudo M, Finn R, Galle PR, Blanc J, Okusaka T, et al. Ramucirumab As Second-
Line Treatment in Patients with Hepatocellular Carcinoma (HCC) and Elevated Alpha-
Fetoprotein (AFP) Following Sorafenib: Pooled Results from Two Global Phase 3 Studies 
(REACH-2 and REACH). Hepatology 2018;68, suppl. 
[130]Park J-W, Kim YJ, Kim DY, Bae SH, Paik SW, Lee Y-J. Sorafenib with or without concurrent 
transarterial chemoembolization in patients with advanced hepatocellular carcinoma: a phase 
III STAH trial. J Hepatol 2018;In Press. 
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Reviewer #3:  
 
The revised version has improved the overall message of the manuscript although there 
is still a tendency, as the first reviewer notes, for the authors to placate the reviewer by 
agreeing with their criticisms and then to make no related charges in the text. 
 
[Trial data belongs to the company sponsoring the study. Further exploring so is far 
beyond the scope of this review] 
Understood, But the question is, do the authors have access to the raw data on which 
SHARP and the AP studies were based? Are they in a position to undertake their own 
independent analyses? Or have the trial results and all the subsequent downstream 
analyses been undertaken by the company? 
 
We have made some changes addressing this issue. Please see response to Reviewer #1. 
 
[To answer the question about the comparison between different radiological criteria, 
this concept should be addressed in an independent meta-analysis with trials using 
RECIST or mRECIST] 
Agreed. Then since radiological criteria of response are central to this review, the 
author's stance should surely be, words to the effect that, the optimal method of 
assessing response has not yet been defined and awaits an independent meta-
analysis.  Then, by all means continue 'nonetheless recent studies…suggest'. But if this 
is done the caveats described by Bruix et al (Journal of Hepatology 2017 vol. 66 1114-
1117) should be noted for balance. 
As it stands p13 &14 give the impression that mRECIST is clearly superior. 
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We have modified this section of the text to better reflect the controversy regarding methods to 
evaluate tumor response in HCC. 
 
[Page 14, line 24]: A direct comparison between RECIST and mRECIST for OS surrogacy 
through an independent meta-analysis of trials using either criteria would be ideal to define the 
role of ORR to predict OS in advanced HCC. This will also help determine the best tool to 
evaluate tumor response to systemic therapies. However, since only 5 RCTs reported response 
data using mRECIST, we did not sub-analyze this endpoint according to the tool used to 
evaluate response. 
 
[In fact, it is not intended that these RECIST guidelines play a role in the decision making 
clinical process] 
Is it not proposed that patients who progress on Sorafenib, according to RECIST 
guidelines, should be moved from Sorafenib to Regorafenib? 
 
The scope of this review is oriented to discuss clinical trial design and recent developments 
based on the recent trials reported in HCC. The current EASL guidelines recommend both 
RECIST and mRECIST to assess response to systemic therapies in HCC, so it is difficult to 
recommend one versus the other with the current data available. Their value is mostly in the 
context of clinical trials, and that’s the main rationale for their initial development (our comment 
was in this direction).  
 
[The signal was not based on response rate, but on median survival time of the patients 
receiving sorafenib] 
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Understood and point taken. 
 
[Positive and negative trials are defined according to the primary endpoint of the study] 
Understood. Then this should be stated, it is not self-evident. 
 
Table 1 summarizes the criteria used to define positive (for superiority and non-inferiority) and 
negative trails. The primary endpoint of all phase III trials included is OS. 
 
[We agree this comment. The present review focus mainly on RCT but we thought that 
the recent success of checkpoint inhibitors in HCC should be introduced. It is clearly 
stated throughout the manuscript that the accelerated approval of nivolumab is based 
on a phase II single-arm trial] 
The reviewers point was merely that the heading of this section is phase III trials - so 
phase II studies seem inappropriate in this section. 
 
We have modified the heading of the section to better reflect this:  
 
Overview of phase III and practice-changing phase II trials reported during the last 10 years  
 
[If we understand well, the reviewer suggests incorporating additional data regarding 
reference 34, beyond that sorafenib is more effective in HCV-related HCC]  
Yes, if a strength of the SHARP trial is that it was stratified for extra-hepatic disease (EHD), 
then doesn't' figure 1 (A & B) in ref 34 (and the associated tables [4]) become an important 
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finding? Shouldn't the fact that in this analysis there is no obvious benefit for sorafenib 
in EHD patients be noted/commented on in a review of 'randomised trials in HCC?'  
 
The findings observed in the individual-patient data analysis of SHARP and Asian-Pacific trials 
are relevant enough, as mentioned by Reviewer #3, to be included in the present review: 
 
[Page 4, line 29]: Etiology is not considered a prognostic factor, but needs to be incorporated 
when testing sorafenib, since it has been demonstrated to be a predictor of response for this 
drug, at the same level than absence of extrahepatic spread and low neutrophil-to-lymphocyte 
ratio[34]. 
 
[Well, this is the whole purpose of a review, to provide a summary of information but also 
opinions from the authors. I understand that this issue might be debatable, and we are 
open to this debate] 
Well, no.  
The purpose of a review may be to express the opinions of the authors, but the opinions 
should be based on evidence found in a review of the literature. As previously pointed 
out, the authors offer an unreferenced opinion related to an unwritten law from 
unidentified experts. As the authors know well expert opinion is not regarded highly. This 
really matters. Future trials will merely say 'our survival improvement of 2 months is 
considered clinically significant' and reference this review. There will be no 
understanding by the reader that there is no evidence on which this statement is based.  
The alternative is to briefly review the extensive literature on assessment of clinical 
benefit. The ESMO (and/or ASCO) guidelines are a good point to start - ESMO-Magnitude 
of Clinical Benefit Scale version Annals of Oncology 28: 2340-2366, 2017. 
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The review summarizes the views of the authors based on the current available data, and we 
agree that this corresponds to limited level of evidence. Our intention is not to overinterpret the 
data, but to provide a balance view of a key issue that is emerging as a result of the recent 
changes in the systemic therapy arena in HCC. We agree that the definition of clinical benefit is 
controversial, highly dependent on the expected outcome for the target population, with 
confronted opinions between patients, providers, regulatory agencies and health insurers. 
Accordingly, we have deleted the sentence in which 2 months is considered to be clinically 
relevant. In addition, we have included the ESMO guidelines that review this topic in detail. Also, 
we have considered the threshold proposed by ASCO of OS with HR<0.8 as cliinically sound in 
HCC for magnitude of benefit. (Ellis et al, JCO 2014).  
 
[Page 10, line 10]: What is the magnitude of benefit to define it as clinically meaningful? This is 
a controversial topic, highly dependent on the expected outcome for the target population, with 
confronted opinions between patients, providers, regulatory agencies and health insurers 
[81,82]. In HCC, there is no consensus on what absolute survival benefit (or the magnitude of 
benefit in OS as per HR) to be defined as clinically relevant. Reported thresholds of OS with 
HR<0.8 are also sound for advanced HCC trials[83]. An unwritten rule among experts estimate 
that in advanced HCC scenario, where natural outcome (placebo arm) is estimated to be of 
around 8 months, absolute gains beyond 2 months are considered clinically relevant, while those 
below 1 months are not. 
[82] Cherny NI, Dafni U, Bogaerts J, Latino NJ, Pentheroudakis G, Douillard JY, et al. ESMO-
Magnitude of Clinical Benefit Scale version 1.1. Ann Oncol 2017;28:2340–66. 
[83] Ellis LM, Bernstein DS, Voest EE, Berlin JD, Sargent D, Cortazar P, et al. American society 
of clinical oncology perspective: Raising the bar for clinical trials by defining clinically meaningful 
outcomes. J Clin Oncol 2014;32:1277–80. 
[A conservative minimum surrogate threshold effect of HR =0.5 is highly predictive of a 
significant improvement in OS, whereas HR ranging from 0.5 - 0.7 are uncertain 
surrogates] 
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As the authors point out this conclusion is only really supported in the second line 
setting and then against placebo. 
Agreed, see response to Reviewer #1. 
[To facilitate the implementation of biomarker-based clinical trials in HCC, it is essential 
to enforce mandatory tissue collection in all clinical trials testing new compounds[4]] 
If biopsy is now indicated in clinical trials then surely: 
a)     The issue surrounding intra and inter-tumoural heterogeneity needs to be 
mentioned 
b)     'essential to enforce mandatory tissue collection'  Where is this in reference 4?  
 
a) The impact of intratumor heterogeneity is still debated as it impacts single-biopsy predictions. 
We have analyzed the distribution of know driver genes in HCC and it seems that all regions 
harbor this type of alterations (e.g., TP53, CTNNB1, TERT promoter) (Torrecilla et al. J. Hepatol. 
2017, 67, 1222–1231). Other studies have reported similar results (Zhai et al. Nat Commun. 
2017 Feb 27;8:4565; Lin et al.  Cancer Res. 2017 May 1;77(9):2255-2265). In other tumors, 
molecular heterogeneity between primary and metastatic tumors is minimal (Reiter et al. 
Science. 2018 Sep 7;361(6406):1033-1037). We have included a sentence to describe this 
issue: 
[Page 9, line 5]: To facilitate the implementation of biomarker-based clinical trials in HCC, it is 
essential to enforce mandatory tissue collection in all clinical trials testing new compounds[4]. 
In this regard, the impact of intratumor heterogeneity in single-biopsy predictions is still debated 
despite recent studies have shown that driver gene mutations are common between different 
regions of the tumor [76,77]. 
 
[76] Torrecilla S, Sia D, Harrington AN, Zhang Z, Cabellos L, Cornella H, et al. Trunk mutational 
events present minimal intra- and inter-tumoral heterogeneity in hepatocellular carcinoma. J 
Hepatol 2017;67:1222–31. 
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[77] Reiter JG, Makohon-Moore AP, Gerold JM, Heyde A, Attiyeh MA, Kohutek ZA, et al. Minimal 
functional driver gene heterogeneity among untreated metastases. Science 2018;361:1033–7. 
 
b) One of the EASL HCC guidelines recommendations for trial design and endpoints is:   
• Upfront liver biopsy and blood sampling is recommended for clinical and diagnostic trials 
(recommendation strong). 
 
[Is worth to mention though that this rule is supported mainly by positive trials in the 
second-line setting comparing active drugs vs placebo. We assume that such 
association is retained in front-line comparing two active drugs, but recommendation in 
that setting should be tempered due to the lack of confirmatory data] 
Agreed, and the authors seem, in this statement, to undermine the main thesis of this 
review. 
 
They are making a major assumption when all three trials with HR <0.5 are indeed second  
line against placebo and, as they acknowledge, there is 'lack of confirmatory data to 
support this assumption' [in other scenarios]. Yet in the conclusion we find 'Thus, PFS-
HR =0.5 can be considered a candidate endpoint in phase II and phase III RCTs when 
subsequent therapies are expected to impact overall outcome'. 
 
Agree, please see response to Reviewer #1. We mention the potential discrepancy between 
results in first and second line to provide a balance view of our interpretation of the data and 
underscore its potential limitations.  
 
Their language must be much more 'tempered' in the conclusions. 
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As suggested by Reviewer #3 we have tempered the statement that suggests PFS-HR ≤0.6 as 
a candidate endpoint in advanced HCC: 
 
[Page 15, line 58]: Thus, PFS-HR ≤0.6 could be considered a candidate endpoint in phase II 
and phase III RCTs when subsequent therapies are expected to impact overall outcome. 
 
Reviewer #4: 
 
1.     The structure of the paper does not identify clearly a Methods section where we 
would learn exactly how was the study conducted and which analyses were done 
precisely. For instance, the end of introduction already gives results. This is perhaps 
because it is an invited review, but since it aims at providing scientifically grounded 
recommendations, it should follow the standards for scientific reporting, so that we are 
able to evaluate the content. 
 
We thank Reviewer #4 for this relevant comment. However, as pointed out, this is not an original 
article and a methods section is not allowed. We thought that the analyses conducted increase 
the interest of the review and provide new tools for the successful development of clinical trials 
in advanced HCC. In the manuscript and figure legends, we have defined the method used for 
the development of the meta-analysis of trial-level surrogate endpoints: 
 
[Page 11, line 25]: The Institute for Quality and Efficiency in Health Care has proposed a set of 
criteria to quantify the association between a surrogate and hard endpoint, which includes low 
(R<0.7), moderate (R>0.7 to R<0.85) and high correlation (R>0.85)[89]. R refers to the weighted 
Pearson coefficient between HR of OS and HR of the surrogate endpoint. 
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2.     Clearly, the selection of the trials for analysis is crucial for the conclusions. I have 
no idea whether SHARP and AP trials should be part of this review or not, but the trials 
included should be according to clearly predefined eligibility criteria. The type of drug 
can be part of the eligibility criteria, the important point being to be clear upon that. It is 
also important to perform a thorough literature search, and to include all trials according 
to the eligibility criteria, especially if no individual patient data are used. 
 
The data of SHARP and AP trials are included for the TTP but not for the PFS correlation since 
these studies did not report PFS. Previous reviewers have asked for this information, but we do 
not have access to individual patient data to calculate PFS in these trials (see comments to 
Reviewer #1 for details). As recommended, we have clarified the criteria used to select the 21 
trials included in the analysis: 
 
[Page 11, line 32]: In order to explore the concept of surrogate endpoints recapitulating OS in 
advanced HCC we have identified 21 RCTs assessing systemic therapies with or without loco-
regional therapies in advanced HCC (12 in first-line and 9 in second-line) (Table 1) published 
between 2008 and 2018 through a MEDLINE search via PubMed using the keywords “advanced 
hepatocellular carcinoma”. Results were limited to “clinical trial, phase III”. Trials recently 
presented at international meetings (2016-2018) were also included despite the full manuscript 
is not yet available. For each trial, data on sample size, radiological response, TTP and OS were 
collected. TTP and OS were determined in terms of hazard ratio (HR) using published data 
(values less than 1 denotes a favourable result in the experimental group). In addition, ORR 
was established with odds ratio calculated from the published radiological response (values 
greater than 1 denotes a favourable result in the experimental group). 
3.     Validation if surrogate outcomes can involve patient-level and trial-level analyses. 
At the patient level, the question is e.g. what is the association between a given PFS and 
OS for a particular patient. At the trial level, the question is rather what is the association 
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between a given amount of effect on PFS on the treatment effect on OS. Both are very 
different. Only individual patients data allow to study the first type of surrogacy. Here my 
view is that only the second one was studied—which I find the most interesting by far—
but this should be clarified, and the wording should be adapted for that aim. 
 
We agree with Reviewer #4 about the two types of surrogacy: patient-level and trial-level. That 
was already acknowledged in the manuscript: 
 
[Page 11, line 20]: Validation of surrogate endpoints can be conducted at the individual- or trial-
levels[88]. While validation of individual-level surrogacy requires individual patient data from at 
least one clinical trial, trial-level surrogacy uses assembled data from multiple trials. 
 
In order to stress the type of the analysis conducted in the present review, we have added ‘trial-
level’ in the sentence describing the methodology: 
 
[Page 11, line 43]: For the purpose of the trial-level analysis, we first assessed the overall 
correlation between PFS and OS (R=0.84; R2=0.71) (Figure 3A), and then the correlation of TTP 
and OS (R=0.83; R2=0.69) (Figure 3B). 
 
4.     Methods for surrogate outcome validation are complex. The reference 80 is 
absolutely correct, but there are also other references that should be used to describe 
(and determine) the methods. For instance papers by Ciani and colleagues in the Journal 
of Clinical Epidemiology and the BMJ. Then these methods should be described. For 
instance I do not know whether the gray shaded areas around the regression lines on the 
surrogacy plots represent confidence intervals or prediction intervals (and we need the 
latter here). 
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We agree that there are different methods to study surrogacy in clinical trials. Indeed, the 
different methods vary in terms of definition of endpoints, measurement of differences between 
treatments and statistical tools to grade the correlation observed. The revised version mentions 
that there are alternative methods to conduct this analysis as reported in advanced colorectal 
cancer by Ciani et al:  
 
[Page 11, line 28]: R refers to the weighted Pearson coefficient between HR of OS and HR of 
the surrogate endpoint. Alternative methods to study this correlation have been reported[90]. 
 
[90] Ciani O, Buyse M, Garside R, Peters J, Saad ED, Stein K, et al. Meta-analyses of 
randomized controlled trials show suboptimal validity of surrogate outcomes for overall survival 
in advanced colorectal cancer. J Clin Epidemiol 2015;68:833–42. 
 
On the other hand, we have added in figure legends the meaning of the gray shaded areas 
around the regression lines on the surrogacy plots: 
 
Gray shaded areas represent the upper and lower limits of the 95% confidence intervals for the 
regression.  
 
5.     TTP is a complex outcome. The manuscript mentions the problem of competing risks 
for PFS, but actually, from a statistical point-of-view, there is no such issue. The issue is 
more that death can be due to various reasons, some being unrelated to the underlying 
cancer or treatment effect. But this is part of the outcome definition, as OS for instance. 
On the contrary, TTP necessitates the handling of competing risks. So it may be relevant 
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to mention it, and to explain how data have been analyzed. There are several ways 
(basically two) to handle competing risks. Either cause-specific hazard ratios are 
computed (this works as if deaths were censored, so I assume this is what the authors 
refer to), or subdistribution hazard ratios. Both being possibly different, they deserve 
separate validation for surrogacy. So this should be made explicit. 
 
We thank the reviewer for bringing up the issue of competing risks. In the randomized clinical 
trials assessed for TTP, deaths were censored as non-radiological progressions at the time of 
death or at an earlier visit, with a cause-specific hazard, meaning that the risk set decreases 
each time there is a death. We have clarified this in the revised manuscript: 
 
[Page 12, line 37]: Deaths are censored as non-radiological progressions at the time of death 
or at an earlier visit, with a cause-specific hazard, representing informative censoring. 
 
6.     On a slightly similar issue, at least a subgroup analysis for RECIST and mRECIST 
should be used. These being different response criteria, it should be useful to see 
whether they perform similarly or not as surrogates. 
 
This issue was already raised in the first point by point review in which Reviewer #4 was not yet 
included. We did consider conducting this sub-analysis for the manuscript, but we decided not 
to include it since mRECIST was only reported in 5 HCC randomized trials [10,13,18,19,22]. 
Thus, we believe that this sub-analysis would be severely underpowered and potentially 
misleading. We have included a clarification to highlight this limitation:  
 
[Page 14, line 24]: A direct comparison between RECIST and mRECIST for OS surrogacy 
through an independent meta-analysis of trials using either criteria would be ideal to define the 
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role of ORR to predict OS in advanced HCC. This will also help determine the best tool to 
evaluate tumor response to systemic therapies. However, since only 5 RCTs reported response 
data using mRECIST, we did not sub-analyze this endpoint according to the tool used to 
evaluate response. 
 
7.     According to usual definitions (and I'm unsure they were used here) a surrogacy 
threshold of 0.5 indicates poor surrogacy. So the main conclusions for me is that PFS 
should rather not be used as a surrogate here. 
 
Please see response to Reviewer #1. The value of 0.5 to define poor surrogacy refers to the 
correlation between endpoints. The correlation between PFS and OS in HCC is 0.84 (see page 
12 of the revised manuscript) which indicates a moderate correlation. We discuss the use of a 
more stringent value of the HR for PFS (below 0.6) to increase its accuracy to predict OS.  
 
8.     I did not see the point of assessing the surrogacy of TTP for PFS. PFS is already a 
surrogate outcome by itself, and this is of no use if TTP is also assessed for surrogacy 
to OS. 
 
We agree with Reviewer #4 in this point. However, the reason to include the correlation between 
TTP and PFS was a specific request from the Editorial Team of the journal in previous revisions 
of the paper. However, we recognize that Figure 4 is still informative since it shows a strong 
correlation between both endpoints. In the modern era of HCC trial design, this suggests minimal 
cirrhosis-related deaths due to restricting patient inclusion to those with well-preserved liver 
function (Child-Pugh A). 
Less major points are: 
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1.     It is unclear in the article how studies are categorized as positive or negative on the 
plots. Is it the primary outcome of the trial? Or always OS? (could be the same, of course). 
It would be interesting to classify the points as significant effect on PFS and OS, 
significant for PFS-NS for OS, NS for PFS-significant for OS, NS for both. 
 
We have added in figure legends how studies are categorized:  
 
Trials are colored based on whether the final result was positive, negative or non-inferior for the 
primary endpoint (OS). 
 
In Table 1 readers can easily identify those trials where the active arm induced significant 
differences in one endpoint but not in the others. 
 
2.     In the table, HRs should be given with confidence intervals. 
 
As suggested, we have added confidence intervals in Table 1. 
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Summary 
Hepatocellular carcinoma (HCC) is a relevant cause of cancer-related mortality worldwide. 
Around half of HCC patients will receive systemic therapies during their life span. The pivotal 
positive sorafenib trial and regulatory approval in 2007 was followed by a decade of negative 
studies with drugs leading to marginal anti-tumoral efficacy, toxicity, or trials with lack of enrichment 
strategies. This trend has changed during the period 2016-18, when several compounds such as 
lenvatinib (in first line) and regorafenib, cabozantinib, ramucirumab and nivolumab (in second-line) 
showed clinical benefit. These successes came at a cost of increasing the complexity of decision-
making, and ultimately, impacting the design of future clinical trials. Nowadays, life expectancy with 
single active agents has surpassed the threshold of 1 year and the field is facing encouraging 
outcomes ~2 years with sequential strategies. Overall survival (OS) remains as the main endpoint in 
phase III investigations, but as in other solid tumors, there is a clear need to define surrogate 
endpoints that both reliably recapitulate survival benefits and can be assessed prior additional 
efficacious drugs are administered. A thorough analysis of 21 phase III trials published in advanced 
HCC demonstrated a moderate correlation between progression-free survival (PFS) or time to 
progression (TTP) with OS (R=0.84 and R=0.83, respectively). Nonetheless, significant differences 
in PFS were only followed by differences in survival in 3 out of 7 phase III studies. In these later 
cases, the magnitude of benefit for PFS was HR ≤ 0.6, and thus this threshold is herein proposed 
as a potential surrogate endpoint of OS in advanced HCC. Conversely, PFS with a HR between 0.6-
0.7, despite significant, was not associated with better survival, and thus these magnitudes are 
considered uncertain surrogates. In the current review, we discuss the reasons for positive or 
negative phase III trials in advanced HCC, and the strengths and limitations of clinical surrogate 
endpoints (PFS, TTP and objective response rate [ORR]) to predict survival.  
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Introduction 
The incidence of hepatocellular carcinoma (HCC) is increasing and will soon surpass one 
million annual cases worldwide[1]. Up to 80% of HCC patients have concomitant liver cirrhosis, 
mainly as result of hepatitis B and C virus infection, alcohol abuse or non-alcoholic steatohepatitis in 
the context of metabolic syndrome[2]. Coexistence of cancer and cirrhosis in HCC is an essential 
hallmark that has shaped clinical trial design in HCC, as encapsulated in the Barcelona Clinic Liver 
Cancer (BCLC) algorithm[3,4]. Only 40% of HCC patients are diagnosed at early stages, when 
potentially curative treatments (i.e. resection, liver transplantation and local ablation) are 
applicable[4]. As disease progresses, transarterial chemoembolization[5] (for intermediate HCC) 
and systemic targeted therapies[6] (for advanced HCC) have shown survival benefits. Since 
sorafenib positive impact in survival[7], at least 10 trials have shown negative results in front-line. In 
the last 2 years, however, numerous systemic agents have demonstrated clinical benefit in the 
context of phase III trials. The fact that six drugs are currently effective and/or approved by the Food 
and Drug Administration (FDA) for the management of advanced HCC poses a challenge for 
assessing novel strategies in this arena in terms of trial design. Overall survival (OS) is an 
unquestionable, unbiased primary endpoint in oncology and in all randomized studies testing 
systemic therapies in first and second line in advanced HCC[7-27]. However, other solid tumors 
have identified surrogate endpoints of survival that led to accelerated and regular approval, notably 
objective response rate (ORR) and progression free survival (PFS)[28,29]. These endpoints are 
aimed to recapitulate survival benefits with the advantage of being assessed prior additional 
efficacious drugs are administered. By thoroughly analyzing the past experience since sorafenib 
approval, we have assessed the correlation between surrogate endpoint such PFS, time to 
progression (TTP) and ORR with clinically meaningful improvements in OS in 21 reported phase III 
studies[7-27]. Based on this analysis and a conservative approach to define surrogates of OS in 
HCC, we propose PFS with a threshold of HR≤ 0.6 as reliable surrogate with solid positive 
predictive value, whereas the threshold of HR=0.6-0.7 -despite leading to positive statistical results- 
is defined as clinically uncertain in terms of capturing true advantages in OS. In addition, we revisit 
the correlation between ORR by mRECIST and OS and define again that ORR is an independent 
predictor of OS at early, intermediate and advanced stages, meaning that responders survive 
significantly longer. Nonetheless, ORR is still a suboptimal tool as surrogate due to the low 
sensitivity in capturing those patients that benefit from a given drug. Ultimately, we envision 
providing a historical perspective of HCC trial design, which are the lessons to be learned, and how 
to maximize clinical trials success in the near future. 
 
Overview of phase III and practice-changing phase II trials reported during the last 10 years  
Current estimates suggest that around 50% of HCC patients will receive systemic therapies 
at one time point or another during their lifespan [2,4,30]. Several trials have tried to show survival 
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benefits of systemic agents in advanced disease, a traditionally challenging setting due to the limit 
efficacy and high toxicity of conventional systemic chemotherapy[16–18,31]. Randomized studies 
also failed to prove any clinical efficacy for anti-estrogen therapies[32]. In 2008, the landmark 
SHARP trial assessing the multi-tyrosine kinase inhibitor sorafenib (VEGFRs, PDGFRs, RAF and 
KIT) was the first to significantly expand survival (hazard ratio (HR) of 0.69) with manageable 
adverse events[7]. Similar efficacy was demonstrated in the phase III trial testing sorafenib in Asian 
patients[8]. These successful results helped established contemporary concepts in trial design that 
have been implemented in phase III trials over the succeeding years (Table 1 and Figure 1)[33]. 
The main concepts implemented in these trials are: a) selection of patients with well-preserved liver 
function (i.e., Child-Pugh A class) to minimize the competing risk of liver failure and death as a 
result of the natural history of cirrhosis; b) restriction of the investigational niches to those stages 
with unmet medical needs such as advanced stage (BCLC C), or intermediate stage (BCLC B) 
progressing after TACE in case of systemic treatments or adjuvant setting after resection/local 
ablation; c) use of OS as the cornerstone primary endpoint to assess efficacy in advanced stages, 
and d) use of critical prognostic factors as tools for stratification prior randomization based upon 
ECOG 0 vs 1, macrovascular invasion, extrahepatic spread, and alpha-fetoprotein (AFP) levels 
(>400 ng/ml). Etiology is not considered a prognostic factor, but needs to be incorporated when 
testing sorafenib, since it has been demonstrated to be a predictor of response for this drug, at the 
same level than absence of extrahepatic spread and low neutrophil-to-lymphocyte ratio[34].  
In this context, new treatment modalities emerged to challenge sorafenib in first-line or 
placebo in second-line. These include brivanib (VEGFRs and FGFRs)[10,19], sunitinib (VEGFRs, 
PDGFRs and KIT)[9], linifanib (VEGFRs and PDGFRs)[11], erlotinib (EGFR) in combination to 
sorafenib[12], everolimus (mTOR)[20], tivantinib (MET)[23], doxorubicin loaded nanoparticles[27] 
and ADI-PEG 20 (arginine deiminase enzyme)[26] (Table 1). All of them had disappointing results 
and it was not until 2016 that the RESORCE study led to the first positive phase III trial in advanced 
HCC for nearly a decade. Regorafenib (VEGFRs, PDGFRs, KIT and Tie2) improved OS compared 
to placebo from 7.8 to 10.6 months in patients who progressed and were tolerant to sorafenib[22]. 
Notably, OS from starting sorafenib follow by regorafenib was 26 months compared to 19 months 
for sorafenib followed by placebo for patients with advanced HCC [35]. Besides regorafenib, other 
phase III clinical trials have recently improved OS in second-line when compared to placebo: The 
CELESTIAL study, showing median OS of 10.2 months with cabozantinib  (VEGFRs, MET and 
AXL) vs 8 months with placebo[24]; and the REACH-2 study, where ramucirumab (VEGFR2 
monoclonal antibody) provided a median OS of 8.5 months in patients with AFP equal or higher 
than 400 ng/ml vs 7.3 months with placebo[21,25]. AFP is well-known for its independent prognostic 
capacity in HCC[36]. As such, REACH-2 becomes the first positive phase III trial in a biomarker-
driven population of HCC patients. In parallel, lenvatinib (VEGFRs, FGFRs, RET, KIT and 
PDGFRA) has become an option in frontline after the positive result of the non-inferiority REFLECT 
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study[13]. In contrast, three phase III trials testing internal radiation with Y-90 for advanced HCC, 
either as single treatment [SARAH[14] and SIRveNIB[15]] or in combination Y-90 plus sorafenib[37] 
did not meet the primary endpoint of improved OS compared to sorafenib. As a result, Y-90 is 
discouraged for the management of advanced HCC in the recent EASL guidelines[4]. 
Finally, the FDA has granted accelerated approval to the immune checkpoint inhibitor 
nivolumab (monoclonal antibody against PD1) in second-line after a large phase II single-arm trial 
showing promising ORR of 14% by RECIST (responses lasting more than 12 months in 55% of 
cases)[38,39]. Pembrolizumab has recently shown an ORR of 17% and median OS of 12.9 months 
in the second-line setting[40]. The revolution of immune therapies that has changed the paradigm of 
treatment in oncology is now finding its way in HCC, with ongoing phase III in both first- 
(NCT02576509, NCT03298451, NCT03434379, NCT03713593) and second-line (NCT02702401) 
targeting key mediators of the anti-cancer immune response (e.g., PD1, PDL1, CTLA4, LAG3). 
Overall, these successful results have amplified the number of effective drugs available to clinicians 
for the management of advanced HCC (Figure 2). New studies will be crucial to ascertain the most 
efficient way to utilize these drugs and maximize clinical benefit. 
 
Reasons for positive/negative results in phase III investigations 
 
Negative phase III clinical trials 
Until 2016, sorafenib was the only systemic agent able to significantly increase survival in 
patients with advanced HCC[7]. This was despite numerous attempts to improve, or parallel (i.e., 
non-inferiority trials), its efficacy and develop new second-line therapies in the context of phase III 
trials (Table 1). Until then none of the 8 randomized clinical trials (RCTs) testing systemic 
treatments (vs sorafenib in front line[9–12,17] or placebo in second-line[19–21]) was able to achieve 
positive results. Nowadays, 6 of 21 (29%) trials have been able to meet the primary endpoint and 
potentially change the standard of care. This success rate is lower than in other tumor types, with 
reported success rate of 37%[41], and resonates with the difficulties of developing effective drugs in 
HCC. Negative HCC trials enrolled a total of 8,604 patients and consumed a significant amount of 
resources. Failed drugs include linifanib[11], erlotinib[12], brivanib[10,19], sunitinib[9], 
doxorubicin[17,27], everolimus[20], tivantinib[23], ADI-PEG 20[26] and radioembolization with Y-
90[14,15] (Table 1). These drugs have different molecular targets, mechanisms of action, and 
include various treatment modalities (pharmacological vs radiation-based). Thus, it is likely that 
multiple reasons contributed to their failure, but we will dissect three key factors, reviewed in [42]: a) 
limited anti-tumoral efficacy (or biological activity), b) significant toxicity, and c) lack of effective 
enrichment strategies for patient enrollment.  
Limited anti-tumoral efficacy (or biological activity) 
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The first factor relates to limited anti-tumoral activity of the drug as per its main molecular 
targets. This implies that either they have a marginal role in HCC progression, or their selective 
inhibition is insufficient to induce a significant clinical benefit. For instance, evidence from murine 
models demonstrated how aberrant activation of MTOR signaling promotes liver cancer[43], and 
how its selective abrogation has anti-tumoral effects in xenografts[44]. In human HCC, MTOR 
pathway is deregulated in up to 45% of samples[44,45], and yet, the phase III trial testing 
everolimus was unable to improve survival compared to placebo in second line with a HR for OS of 
1.05[20]. Data in phase II already suggested a modest median survival of 8.4 months[46] 
associated to marginal response rates. Also, the companion biomarker study for the phase III trial 
failed to find any robust predictive biomarker of response to everolimus[47]. Altogether, these data 
suggest that MTOR inhibition has no anti-tumoral activity in advanced HCC. Other drugs potentially 
falling under this category include the EGFR inhibitor erlotinib[12], and the FGFR2/VEGFR inhibitor 
brivanib[10,19]. Limited efficacy can also be claimed for Y-90 resin microsphere treatment as a 
superior alternative to sorafenib. The phase III trials reported[14,15], were negative with a HR for 
OS of 1.1. It is important to note that failure to demonstrate superiority does not mean similar 
efficacy, which requires an ad hoc trial design for non-inferiority or equivalence, a concept that will 
be further discussed in this review[48].  
Drug toxicity 
The second reason is significant drug toxicity, which is relevant in cirrhotic patients since 
liver dysfunction decreases the threshold for severe adverse effects. The best example is 
sunitinib[49], that despite having a molecular target profile similar to sorafenib, it was unable to 
improve survival when compared in frontline[9]. The trial was prematurely terminated due to futility 
and safety concerns affecting sunitinib. Median OS for sunitinib was 7.9 months, compared to the 
10.2 with sorafenib (HR of 1.3). Treatment-related deaths occurred in 3.2% and 0.4% of patients 
receiving sunitinib and sorafenib, respectively. When this trial was conducted, sunitinib was already 
FDA approved for advanced kidney cancer and gastrointestinal stromal tumors, where toxicity was 
not a major clinical issue. However, in patients with underlying liver disease the toxicity of sunitinib 
was severe enough to obscure any beneficial anti-tumoral efficacy. Sunitinib has a higher inhibitory 
potency than sorafenib, particularly regarding its anti-angiogenic activity via VEGFR and PDGFR 
Inhibition[50]. Angiogenesis is critical during liver fibrogenesis[51], so the strong and sustained anti-
angiogenic effect achieved with sunitinib seems detrimental, favoring liver failure. Previous phase II 
trials testing sunitinib in HCC offer additional insights into the hepatic toxicity of this drug[52–54], 
including up to 4/37 (11%) treatment-related deaths[54]. An adequate identification of toxicity 
signals at this stage could help mitigate this problem. Another example is the VEGFR/PDGFR 
inhibitor linifanib, tested in frontline versus sorafenib[11]. This trial was early terminated based on 
futility (median OS for linifanib and sorafenib were 9.1 and 9.8 months), but grade 3-4 adverse 
events were significantly more frequent in linifanib than in sorafenib, including hypertension (21% vs 
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11%) and hepatic encephalopathy (7% vs 3%). Besides the negative effect of toxicity in clinical 
outcomes, there is a subtler effect of non-lethal toxicity as it associates with dose reductions, which 
could also decrease antitumor potency.  
Lack of trial enrichment strategies 
A third reason for clinical trial failure is lack of effective enrichment strategies for patient 
enrollment based on predicted biomarkers of response. Trial enrichment in oncology is closely 
linked to the concept of oncogene addiction. This term describes those molecular alterations, 
generally DNA mutations or chromosomal aberrations, required for cancer cell proliferation and 
survival[55]. There are numerous examples in oncology of survival benefits after a clinical trial 
testing a drug only in those patients with mutations in its target[56] (e.g., ALK rearrangements in 
lung cancer and response to crizotinib[57]). Only 2/21 (10%) phase III trials in advanced HCC 
incorporated patient enrichment, likely due to: a) limited access to tumor tissue in patients already 
diagnosed by noninvasive criteria; and b) few druggable targets among the most common genetic 
alterations in HCC[58,59]. In fact, the most common mutations in HCC (TERT promoter, CTNNB1, 
TP53, AXIN1, ARID1A and ARID1B) are untargetable[2,60]. One of them evaluated tivantinib 
versus placebo in second line in patients with high expression of MET assessed with 
immunohistochemistry[23]. This trial was based on a post-hoc analysis of 37 patients from a 
previous phase 2 trial[61] and failed to meet its primary endpoint with a HR for OS of 0.97. 
Arguably, the signal in the phase 2 trial was weak, but most important, recent data questions the 
specificity of tivantinib as a MET inhibitor[62]. It was also thought that MET was a prognostic factor, 
but the median survival of 9.1 months for the placebo arm in MET-high patients in second-line 
challenges this concept[23]. The second trial tested the VEGFR2 monoclonal antibody ramucirumab 
versus placebo in second line (i.e. REACH-2) in patients with AFP higher than 400 ng/mL, and 
showed a significant improvement in OS versus placebo (HR of 0.71[25]). A difference with the 
tivantinib case is that the rationale for REACH-2 came from a post hoc analysis of the negative 
phase III trial in all-comers (i.e., REACH[21]) which enrolled 565 patients. This showed a robust p of 
interaction favoring ramucirumab in patients with high AFP of 0.02. AFP is a well-known poor 
prognostic marker[36,47], highly expressed in tumors with a supposed progenitor cell origin[63], but 
it does not provide a neat link between any specific driver oncogenic event (i.e., structural DNA 
alteration or signaling pathway) and ramucirumab’s main molecular target. Experimental evidence 
identifies VEGFR2 as a marker of hepatic progenitors[64], which could hypothetically explain the 
efficacy of ramucirumab in tumors with high AFP.  
 
Positive phase III clinical trials 
Successful drugs in frontline include sorafenib and lenvatinib, whereas regorafenib, 
cabozantinib, and ramucirumab in patients with high AFP demonstrated efficacy in second line 
(Table 1 and Figure 2). The PD1 inhibitor nivolumab has shown promising results in phase II with an 
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ORR of 14% by RECIST (18% by mRECIST) and a median OS of 15.6 months [38,65], which 
granted its accelerated approval by the FDA. Another immune-based therapy -pembrolizumab- 
reported similar ORR (17%) but lower median OS (12.9 months[40]). Data from phase III trials in 
first-line (nivolumab vs sorafenib) and in second-line (pembrolizumab vs placebo) will be critical to 
fully recommend these immune-based therapies in clinical practice guidelines[4]. Since the strength 
of evidence so far comes from phase II data, current EASL guidelines just posed a weak 
recommendation for nivolumab[4].  
The reasons for trial failure provide the best clues for the qualities of a drug to be successful 
in HCC, which essentially are: a) adequate clinical trial design with an emphasis on selection criteria 
and robust endpoints; b) a fine balance between drug efficacy and toxicity; and c) a proper 
interpretation of efficacy and toxicity signals in phase II trials. Sorafenib epitomizes these qualities, 
and to certain extent, the design principles implemented in the pivotal SHARP trial[7] were adopted 
as best-practices for design in subsequent studies[33]. The target population must include patients 
with well-preserved liver function (i.e., Child-Pugh A with compensated liver disease) to avoid 
competing risks from deaths due to progression of the liver disease, and to minimize drug toxicity. 
Also, patients need to be fit enough to tolerate the drug and with a life expectancy of at least 3 
months, which can be reasonably guaranteed by enrolling patients with ECOG performance status 
test (PST) of 0-1. It is paramount to enroll patients at the same clinical stage as per the BCLC 
classification[4,66]. The SHARP trial was instrumental to eradicate the misleading concept of 
‘unresectable’ HCC when conducting HCC trials. This concept included a heterogeneous population 
of patients at intermediate (BCLC-B) and advanced (BCLC-B) stages[67], which imposed significant 
bias when interpreting trial results. In addition to the same clinical stage, patients need to be 
adequately stratified for known HCC prognostic factors and geographic region. 
Regarding patient’s selection, the success of the REACH-2 trial underscores the importance 
of properly interpreting post hoc analysis. The pooled analysis of REACH and REACH-2 assessing 
ramucirumab in those patients with AFP > 400 ng/mL further confirms a significant and clinically 
meaningful benefit of ramucirumab vs placebo in second-line (median survival 8.1 vs 5 months; 
HR=0.694)[25]. The rationale to enrich trials based on predicted oncogene addiction is two-fold: 
first, to maximize anti-tumoral response by perturbing the cancer drivers active in a given patient, 
and second, to spare unnecessary toxicity in those patients without the oncogene addiction. HCC 
has few druggable targets among the most frequent driver mutations, but a recent proof-of-concept 
trial reinforces the validity of this approach to explore treatment response[68]. A screening of 1,318 
HCC patients allowed enrolling 54 cases with RAS mutations (4.4%) detected using circulating 
tumor DNA (ctDNA) in a phase II trial testing the combination of sorafenib with the MEK inhibitor 
refametinib[68]. Mutation analysis of ctDNA is feasible in HCC[69] and facilitates screening of large 
populations. Other potential druggable oncogenic alterations in HCC include high-level DNA 
amplifications of FGF19[70,71] or VEGFA[70,72]. Phase II clinical trials are currently exploring 
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selective inhibition of these candidate oncogene addition loops[73]. There is also increasing interest 
in developing biomarkers to identify the 20% of patients who respond to immune-based therapies, 
who show outstanding OS. The use of PD-L1 staining seems irrelevant in HCC[38], and other 
potential biomarkers such as tumor mutational burden (TMB)[74] or the HCC immune class[75] are 
under investigation. To facilitate the implementation of biomarker-based clinical trials in HCC, it is 
essential to enforce mandatory tissue collection in all clinical trials testing new compounds[4]. In this 
regard, the impact of intratumor heterogeneity in single-biopsy predictions is still debated despite 
recent studies have shown that driver gene mutations are common between different regions of the 
tumor[76,77]. 
Traditionally, new therapies were compared with standard of care or placebo to demonstrate 
greater efficacy of the new drug. Despite this is the recommended trial design practice in 
HCC[4,33], some studies after SHARP used non-inferiority designs to challenge sorafenib in first-
line. The hypothesis in non-inferiority trials is that the new compound is not substantially worse than 
the current standard, as opposed to equivalence trials, which are designed to demonstrate that the 
experimental treatment is neither worse not better than the standard therapy[78]. Non-inferiority 
trials are required to claim similar efficacy as opposed to assuming it from a negative superiority 
trial, as previously explained for the Y-90 trials. The non-inferiority trial scenario in HCC is 
extensively described elsewhere[42], and caveats include the need for larger sample sizes and a 
very small window of opportunity, as defined by the tight non-inferiority margins. For instance, the 
BRISK-FL trial was designed to demonstrate non-inferiority of brivanib compared to sorafenib in first 
line[10]. The trial assumptions set the upper limit of the 95% confidence interval of HR for OS to 
1.08. To call non-inferiority, the HR could cross 1, but the upper boundary needed to fall between 1 
and 1.08. This threshold is very stringent and can be interpreted as the requirement to demonstrate 
a robust non-significant trend towards superiority for the new drug. The value proposed by FDA has 
been calculated based upon capturing at least >60% of the survival benefit obtained with 
sorafenib[13]. The BRISK-FL trial did not meet this endpoint since the HR confidence interval limits 
for OS were 0.94 and 1.23. The concept of non-inferiority trials introduces other considerations in 
treatment recommendations such as toxicity or cost, which will surely contribute to frame the 
landscape of systemic therapies in HCC.  
 
Hard and surrogate endpoints: Implications in clinical trial design  
The overreaching goal of oncological treatments is to allow patients to live longer and better 
lives than they would do without treatment[79]. Thus, clinical research needs to unequivocally 
demonstrate statistically and clinically meaningful improvements of the experimental arm over the 
standard of care. Three types of endpoints have been defined: 1. Hard endpoints, such as overall 
survival and cancer-specific survival; 2. Surrogate endpoints such as PFS, TTP and ORR, and 3. 
Patient reported endpoints, such as quality of life (QOL).  
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Overall survival 
This hard endpoint quantifies the time between random trial allocation and death, whatever 
the cause. Since is not subject to investigator bias, OS has been traditionally recommended by 
international HCC guidelines as the primary endpoint for randomized phase III trials testing new 
therapies[80]. In fact, all regular FDA drug approvals in advanced HCC were based upon 
improvements in OS [7,22]. Cancer-specific survival, where only deaths due to cancer are 
considered and noncancer-related deaths are censored, is more difficult to assess in conventional 
trial settings. Deaths due to competing risks, such as liver failure, require a subjective interpretation 
by the investigator, and thus are more prone to bias[33]. 
What is the magnitude of benefit to define it as clinically meaningful? This is a controversial 
topic, highly dependent on the expected outcome for the target population, with confronted opinions 
between patients, providers, regulatory agencies and health insurers [81,82]. In HCC, there is no 
consensus on what absolute survival benefit (or the magnitude of benefit in OS as per HR) to be 
defined as clinically relevant. Reported thresholds of OS with HR<0.8 are also sound for capturing 
the benefit of patients in advanced HCC trials[83]. 
Survival has some limitations as a sole endpoint in cancer research. First, it might require a 
long follow-up time to capture enough events due to significant improvement in median OS in the 
experimental arm[35]. This negatively impacts feasibility and delays access to patients to highly 
effective drugs. Second, it can be affected by sequential therapies received after tumor progression 
(post-progression survival), such as for instance regorafenib after a first-line therapy. This might 
involve one third of patients in recent phase III trials[13]. In this context, validation of surrogate 
endpoints of OS is paramount to facilitate trial execution and favor a quick deployment of effective 
drugs in routine clinical conditions. 
 
Surrogate endpoints: PFS, TTP and ORR 
Ideally, significant improvement in OS is preferred, but many drugs have been approved 
based on their ability to improve other less robust endpoints, termed surrogates (i.e., TTP, PFS and 
ORR). These are outcomes not inherently meaningful from the clinical standpoint, but thought to 
accurately predict hard outcomes such as OS[84]. The development of surrogate endpoints became 
a necessity in clinical trials in cardiology, where the long time to accumulate enough events for a 
hard endpoint made most studies unfeasible. Use of surrogate endpoints is becoming a need in 
oncology where effective post-progression therapies are available.  
Accelerated approval based upon surrogate endpoints is becoming the most relevant path 
for cancer drug regulatory approval in the US. Between 2009 and 2014; the FDA approved 83 drugs 
in oncology, 66% of them on the basis of surrogate endpoints[85]. The FDA’s accelerated approval 
program was introduced in 1992 as a social compromise during the worse years of the HIV 
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epidemic to expedite access to agents for life-threating conditions based on surrogate endpoints. 
The program included a “safety net” that required the manufacturer to conduct post-marketing 
studies and confirm the efficacy of the drug using hard endpoints[86]. A recent analysis of approved 
drugs during the period 1992-2017 led to the following conclusions[28]: a) Accelerated approval was 
granted for 93 indications, ORR being the most common surrogate endpoint used (87% of cases), 
b) Among drugs approved through this path, 55% were ultimately confirmed for regular approval, 
5% of indications were withdrawn (e.g., bevacizumab in metastatic breast cancer[87]), whereas in 
others the process has not been concluded. 
Despite the increasing importance of surrogate endpoints in oncology, they have two main 
limitations. First, since they usually rely on the radiological definition of tumor progression or 
response, they are vulnerable to interpretation bias. This can be minimized by using central 
radiology reviews and a designated adjudicator of response. Second, and more important, in order 
to be reliable, they require validation as credible predictors of OS[84]. Validation of surrogate 
endpoints can be conducted at the individual- or trial-levels[88]. While validation of individual-level 
surrogacy requires individual patient data from at least one clinical trial, trial-level surrogacy uses 
assembled data from multiple trials. The Institute for Quality and Efficiency in Health Care has 
proposed a set of criteria to quantify the association between a surrogate and hard endpoint, which 
includes low (R<0.7), moderate (R>0.7 to R<0.85) and high correlation (R>0.85)[89]. R refers to the 
weighted Pearson coefficient between HR of OS and HR of the surrogate endpoint. Alternative 
methods to study this correlation have been reported[90]. A systematic review and meta-analysis of 
trial-level surrogate endpoints (PFS, TTP and ORR) for OS in oncology including 36 articles and 
352 clinical trials found low, moderate and high correlation with OS in 52%, 25% and 23% of 
surrogate endpoints, respectively[84]. 
In order to explore the concept of surrogate endpoints recapitulating OS in advanced HCC 
we have identified 21 RCTs assessing systemic therapies with or without loco-regional therapies in 
advanced HCC (12 in first-line and 9 in second-line) (Table 1) published between 2008 and 2018 
through a MEDLINE search via PubMed using the keywords “advanced hepatocellular carcinoma”. 
Results were limited to “clinical trial, phase III”. Trials recently presented at international meetings 
(2016-2018) were also included despite the full manuscript is not yet available. For each trial, data 
on sample size, radiological response, TTP and OS were collected. TTP and OS were determined 
in terms of hazard ratio (HR) using published data (values less than 1 denotes a favourable result in 
the experimental group). In addition, ORR was established with odds ratio calculated from the 
published radiological response (values greater than 1 denotes a favourable result in the 
experimental group). For the purpose of the trial-level analysis, we first assessed the overall 
correlation between PFS and OS (R=0.84; R2=0.71) (Figure 3A), and then the correlation of TTP 
and OS (R=0.83; R2=0.69) (Figure 3B). Afterwards, we established a conservative threshold of 
positive predictive value for PFS since this is the most documented surrogate time-to-event 
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endpoint in oncology, and the one showing a higher correlation with OS[84]. Finally, we explored 
the correlation between ORR assessed as per mRECIST and survival in early, intermediate and 
advanced HCC.  
 
Progression-free survival 
PFS is a composite endpoint of two variables: death and evidence of radiological 
progression, usually defined by standard criteria as RECIST[91] or mRECIST[92]. International 
guidelines initially discouraged this endpoint in HCC due to the competing risk of dying due to 
progressed liver dysfunction despite a relevant anti-tumoral benefit[33]. However, this limitation has 
been mitigated since most trials in HCC have adopted restrictive inclusion criteria in terms of liver 
function (i.e., Child-Pugh A without decompensation). In this scenario, the likelihood of death as a 
result of liver decompensation (i.e., gastrointestinal bleeding, encephalopathy or ascites and 
spontaneous peritonitis) is 5% at one year[93]. When we evaluate the association between PFS and 
OS in HCC phase III trials, we observe a moderate Pearson correlation (R) of 0.84 (Figure 3A). This 
figure falls in the upper boundary of a moderate correlation (R between 0.7 and 0.85). When 
specifically analyzing the positive predictive value of theoretical thresholds of PFS correlating with 
OS, only 3/7 PFS reported a HR ≤0.6 that was significantly associated with a positive survival 
clinical benefit (in all cases with a HR for OS < 0.8). Conversely, those four studies reporting a 
positive PFS with a HR between 0.6-0.8 were associated with no significant survival benefits (HR 
for OS between 0.87 and 1.05) (Figure 3A). In our study, according to the linear regression equation 
obtained [log HROS = 0.072 + 0.487 x log HRPFS], a threshold of PFS HR=0.6 (representing a 40% 
risk reduction) will decrease ~17% the risk of OS (OS HR=0.83) (see Figure 3A). In summary, a 
moderate correlation has been established between PFS and OS in 21 RCTs in advanced HCC. A 
value of HR ≤0.6 is proposed as surrogate threshold effect [94], and is likely to predict a clinically 
meaningful improvement in OS. Is worth to mention though that this rule is supported mainly by 
positive trials in the second-line setting comparing active drugs vs placebo. We assume that such 
association is retained in front-line comparing two active drugs, but recommendation in that setting 
should be tempered due to the lack of confirmatory data. 
Time to progression 
This endpoint quantifies the time between trial allocation and radiological progression, 
usually defined by standard criteria as RECIST[91] or mRECIST[92]. Deaths are censored as non-
radiological progressions at the time of death or at an earlier visit, with a cause-specific hazard, 
representing informative censoring. Symmetric repeated radiological measurements every 6-8 
weeks are required to avoid missing moderate differences between treatment groups[33]. This 
recommendation was not followed in the SIRveNIB[15], SARAH[14] and ADI-PEG 20[26] trials. 
To delineate the adequacy of TTP as a surrogate of OS in HCC we conducted also a trial-
level meta-analysis to evaluate the correlation between TTP and OS in 21 RCTs (Figure 3B). The 
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Pearson correlation (R) was 0.83, which indicates a moderate association according to the IQWIG 
guidelines[84]. In 10 phase III trials there was a significant difference in TTP in favor of the 
investigational arm. However, these positive results in TTP were not followed by superiority in OS in 
5 (50%) trials. Brivanib[19] and ramucirumab[21] in second-line showed efficacy as per TTP 
(HR=0.56 and 0.59, respectively), while not significantly improving the hard endpoint of OS 
(HR=0.89 and 0.87, respectively). Lenvatinib[13] in first-line versus sorafenib also showed 
significant differences in TTP favoring lenvatinib (HR 0.63), without showing superiority for OS 
(HR=0.92). This trial was positive since it was designed for non-inferiority (upper 95% CI lower than 
1.08). Finally, linifanib[11] and hepatic infusion arterial chemotherapy (HAIC)[18] in first-line failed to 
show any benefit in terms of OS (HR=1.05 and 1.01, respectively) even though there was a clear 
benefit when measuring TTP (HR=0.76 and 0.65, respectively). These results do not support the 
initial recommendation after the SHARP trial of using TTP as the optimal surrogate endpoint[33] in 
phase 2 trials, and reinforce the need for accurate evaluation of surrogacy in clinical trials. Based on 
the linear regression model obtained [log HROS = 0.083 + 0.491 x log HRTTP], we can extrapolate 
that a therapy producing a 40% risk reduction in TTP will yield an estimated ~16% risk reduction in 
OS (HR=0.84) (see Figure 3B). Moreover, in order to directly compare the performance of PFS and 
TTP, we analyzed the correlation between both surrogate endpoints, obtaining a Pearson 
correlation (R) of 0.99 (Figure 4). Thus, in the modern era of HCC trial design, with minimal 
cirrhosis-related deaths (due to the inclusion of Child-Pugh A), there is a strong correlation between 
both endpoints. In fact, when we inferred the non-reported PFS HR of SHARP and AP trials 
according to the linear equation obtained comparing both surrogate endpoints [log HRPFS = 0.014 + 
0.927 x log HRTTP], the HRs values are close to 0.60, just at the previously proposed minimum 
threshold. 
There are two other considerations regarding this endpoint. First, not all types of tumor 
progression may have the same clinical meaning. Recent data also suggest that TTP may capture 
heterogeneous features, with essentially two types of progression at advanced stages[95,96]. In 
particular, survival after progression is significantly worse for patients who develop a new 
extrahepatic lesion and/or vascular invasion (median OS = 7.1 months) compared to those who 
progress due to the growth of existing intrahepatic/extrahepatic lesions or the development of a new 
intrahepatic lesion (median OS = 14.9 months). Second, factors including evaluation bias, trial 
attrition or informative censoring may weaken the association between the TTP and OS [29]. 
Finally, prolonged exposure to a given therapy might lead to a phenotypic change in tumors, thus, 
offsetting any initial advantage from the treatment captured by the surrogate endpoint[97].  
Objective response rate 
Tumor response in oncology trials is typically measured using the Response Evaluation 
Criteria in Solid Tumors (RECIST)[91]. These criteria standardize methods for converting 
radiological observations into a quantitative and statistically tractable framework to define tumor 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 
14 
 
response (i.e., a 30% decrease in the diameter of target lesion). ORR is the percentage of patients 
who achieve an objective tumor response. Disease control rate (DCR) is the combination of ORR 
and stable disease, but it has two disadvantages that limit its adoption for regulatory approval: a) 
the definition of duration of stable disease varies between studies; and b) stable disease can reflect 
inherent characteristics of the tumor rather than treatment efficacy. 
The RECIST criteria were originally developed to evaluate cytotoxic agents. The 
generalization of targeted therapies has challenged this simplistic approach that relies on tumor 
shrinkage to indicate clinical efficacy. Sorafenib was associated with only 2-3% of ORR, despite 
providing clear survival benefits[7,8]. Given the poor correlation between tumor response assessed 
with conventional tools and OS, a group of experts convened by the American Association for the 
Study of Liver Diseases (AASLD) proposed specific amendments to standard RECIST[33]. Further 
description of response and progression resulted in the criteria named modified RECIST 
(mRECIST), which ultimately incorporates the concept of viable tumor defined as the portions of 
tumor showing arterial enhancement[92]. The mRECIST criteria in HCC have improved the 
sensitivity to quantify tumor response with targeted therapies: ORR of 9-17% with 
sorafenib[10,13,18], 10-12% with brivanib[10,19], 11% with regorafenib[22] and 24% with 
lenvatinib[13]. Retrospective studies have consistently demonstrated that patients who achieved an 
objective response on sorafenib had a longer survival than non-responders[98–100]. Recently, data 
from double-blind randomized trials assessing brivanib and nintedanib further validated this 
association [101,102]. Thus, the association between tumor response and improved OS in HCC 
patients at advanced stages complement what was already knew in patients at early and 
intermediate stages treated with loco-regional therapies[103–109](Table 2).  
When we evaluate the trial-level correlation between ORR and OS (Supplementary Figure 
1), the R weighted Pearson coefficient obtained is 0.54. This is significantly lower than the 
correlation obtained with PFS/TTP and OS as depicted in Figure 3. There are two reasons for this: 
one is inherent to the use of odds ratio instead of hazard ratio to compare differences in ORR. The 
accuracy of odds ratio decreases for low values of ORRs. The second reason is that only a small 
proportion of patients within these trials achieved ORR (~10-20%), which is, in fact, the event that 
correlates with better survival[101]. A direct comparison between RECIST and mRECIST for OS 
surrogacy through an independent meta-analysis of trials using either criteria would be ideal to 
define the role of ORR to predict OS in advanced HCC. This will also help determine the best tool to 
evaluate tumor response to systemic therapies. However, since only 5 RCTs reported response 
data using mRECIST, we did not sub-analyze this endpoint according to the tool used to evaluate 
response. 
Some other questions remain unanswered. As observed in other solid tumors treated with 
efficacious targeted therapies[110–112], the reported rates of responders are still suboptimal to 
estimate the maximum number of patients who would benefit from the treatment. In addition, the 
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duration of response might be more clinically relevant than the extent of tumor reduction. Finally, the 
strategy to evaluate response might require a thoughtful revision when assessing immunotherapies. 
As shown in melanoma patients treated with checkpoint inhibitors, standard RECIST may not 
provide a reliable assessment of antitumor efficacy[113]. In fact, response to immunotherapy may 
take longer compared to other agents and can even falsely mirror criteria for progression (i.e., 
pseudo-progression)[114]. Immune-related response criteria have been developed[115,116], 
including the concept of “confirmation of progression” by a second scan obtained at least 4 weeks 
after progressive disease has been registered. 
Despite all the challenges that evaluation of tumor response face in oncology, and 
particularly in HCC, the importance of ORR as a surrogate endpoint is recognized by regulatory 
agencies and frequently used for accelerated drug approval. This was the case of nivolumab, 
approved in second-line based on an ORR of 18% by mRECIST and 14% by RECIST [38,39]. 
Remarkably, objective response to nivolumab has been associated with prolonged OS[65]. Overall, 
the fact that a high ORR in phase II trials was considered a robust criterion for drug approval[117], 
and further success in phase III trials[118], indicates that ORR should be considered as a primary 
endpoint for single-arm phase II studies. Related to this, early clinical trials are showing promising 
results with combinations of checkpoint inhibitors and targeted therapies, as measured by ORR. 
Lenvatinib plus pembrolizumab[119] and atezolizumab plus bevacizumab[120] achieved an ORR of 
46% by mRECIST and 50% by RECIST in advanced HCC, respectively. As a result, the later 
combination was granted breakthrough therapy designation by the FDA[121]. Of note, most of the 
drugs approved under the accelerated program reported ORR exceeding 30%[122]. 
 
Patient-reported endpoints: Quality of life 
Health-related QOL measures the effect of the disease on an individual’s physical, 
psychological and social functioning and well-being[123]. Regulatory agencies recognize 
symptomatic improvement as a direct clinical benefit to patients and an important consideration in 
drug approval[124]. However, unlike OS, the interpretation of QOL is subjective. In HCC, two tools 
have been proposed to measure QOL: the European Organization for Research and Treatment of 
Cancer Quality of Live Questionnaire (EORTC QLQ-HCC18)[125] and the Functional Assessment 
of Cancer Therapy-Hepatobiliary (FACT-Hep) questionnaire[126]. They can be used to evaluate 
time to symptomatic progression (i.e. time between trial allocation and the occurrence of disease 
related symptoms according to preestablished scores). QOL was measured in the SHARP trial[7] 
according to the FHSI-8 questionnaire[127], a reduced version of FACT-Hep, with results that 
collided with OS. Conversely, the SARAH trial[14] reported better global health status with Y-90 
when compared to sorafenib based on QLQ-HCC18, which was inconsistent with the primary 
endpoint of OS. Evaluation of QOL is contingent on when it was assessed during disease 
progression. Also, significant changes in QOL have been observed across different cultures[128]. 
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Defining and evaluating reliable QOL assessment tools has been established as one of the unmet 
needs in HCC research by international guidelines[4]. In summary, health-related QOL measures 
are not ready to support, as single tools, regulatory approval for drugs in HCC. 
 
Conclusions 
The current period of drug development in HCC is providing major advancements in the 
management of this devastating disease. Six drugs have currently shown activity as systemic 
therapies, which represents an unprecedented revolution for the last 50 years. Novel drugs or 
combinations strategies are emerging in the field, and thus new tools will be required for the proper 
assessment of clinical benefits. OS is still the most robust endpoint but the increasing number of 
treatments available in advanced HCC preludes the use of surrogate endpoints, less vulnerable to 
subsequent treatments after progression. In this scenario, PFS has shown moderate correlation 
with OS (R=0.84), and a threshold of HR≤0.6 defines a conservative approach of surrogate 
endpoint able to capture survival differences in a superiority trial with a high positive predictive 
value. Two recent studies have been released supporting our threshold of HR ≤ 0.6 for PFS. The 
first one, an individual-patient data meta-analysis of two RCTs (REACH[21] and REACH-2[25]), 
showing a significant OS HR with a PFS HR of 0.57[129]. The second one, a phase 3 RCT 
comparing sorafenib with or without cTACE in advanced HCC, a negative study for its primary 
endpoint (OS) with a PFS HR of 0.73[130]. Thus, PFS-HR ≤0.6 could be considered a candidate 
endpoint in phase II and phase III RCTs when subsequent therapies are expected to impact overall 
outcome. ORR by sensitive criteria (mRECIST) may be useful particularly in single arm phase II 
trials with proof of concept drugs or in combination studies targeting accelerated approval with a 
threshold >30%. Finally, the current development of RCTs assessing immune therapies or drug 
combinations in HCC will certainly evolve the paradigm of drug development and trial design. 
Particularly of interest will be whether the statements proposed in the present review are confirmed 
in trials designed with composite primary endpoints, such as OS-PFS for lenvatinib+pembrolizumab 
vs lenvatinib (NCT03713593) or OS-ORR for atezolizumab+bevacizumab vs sorafenib 
(NCT03434379). 
 
Key points 
 
 In the last two years four systemic agents (i.e., regorafenib, lenvatinib, cabozantinib and 
ramucirumab) have shown clinical benefit in the setting of phase III trials and one (i.e., 
nivolumab) has been granted accelerated approval based on a phase II trial, expanding, thus, 
the pipeline of effective drugs available in advanced HCC to providers. 
 The improvement in the number of effective agents comes at a cost of increased complexity of 
clinical decision-making, and thus, in the design of future clinical trials. 
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 OS is still the most robust endpoint in advanced HCC but the increasing number of treatments 
after progression underscore the need for surrogate endpoints. 
 PFS has a moderate correlation at trial level with OS (R=0.84). A conservative minimum 
surrogate threshold effect of HR ≤0.6 is highly predictive of a significant improvement in OS, 
whereas HR ranging from 0.6 – 0.7 are uncertain surrogates. 
 ORR by sensitive criteria in single arm phase II trials could be a useful tool to prioritize 
treatments for testing in phase III trials. 
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Figure legends 
 
Figure 1: Median overall survival of treatment modalities assessed in phase III trials for 
advanced hepatocellular carcinoma.  
Treatments with more than one dot represent all the results obtained from different clinical trials 
testing the same compound. Trials are colored based on whether the final result was positive for 
superiority (green), negative (red) or positive for non-inferiority (orange) for the primary endpoint 
(OS). Placebo appears in blue. Relevant inclusion/exclusion criteria that may impact on median OS 
are: no portal vein invasion [13], no pulmonary metastases [37], sorafenib tolerant [22], MET high 
[23] and AFP>400ng/ml [25].  
 
Figure 2: Treatment strategy for advanced hepatocellular carcinoma. Adapted from Llovet et 
al. Nat Rev Clin Oncol 2018[6].  
Drugs in green have positive results from phase III trials with a superiority design (sorafenib in the 
first-line setting and regorafenib, cabozantinib and ramucirumab in the second-line setting). Drugs in 
orange have positive results from phase III trials with a non-inferiority design (lenvatinib in the first-
line setting). Drugs in red have received accelerated approval from the FDA on the basis of 
promising efficacy results in phase II trials (nivolumab in the second-line setting). Key details of the 
patient populations are provided. AFP: Alpha-fetoprotein; BCLC: Barcelona Clinic Liver Cancer 
(classification); ECOG PS: Eastern Cooperative Oncology Group performance status; EHS: 
extrahepatic spread; HCV: hepatitis C virus; HR: hazard ratio; mRECIST: modified Response 
Evaluation Criteria In Solid Tumors; ORR: objective response rate; OS: overall survival. 
 
Figure 3: Correlation between surrogate endpoints (PFS[A] and TTP[B]) and hard endpoint 
(OS).  
Trial-level correlation between endpoints using criteria from the Institute for Quality and Efficiency in 
Health Care (IQWIG). R and R2 refers to the weighted Pearson coefficient between the HR of OS 
and the HR of the surrogate endpoint. IQWIG categorizes the strength of the correlation based on 
the value of R as low (R<0.7), moderate (R>0.7 to R<0.85) and high (R>0.85)[89]. Each dot 
represents one of the phase III clinical trials conducted on advanced HCC. Size of the dot is 
proportional to the total number of patients enrolled in the trial. Trials are colored based on whether 
the final result was positive, negative or non-inferior for the primary endpoint (OS). X and Y axis 
depict the value of the HR for the surrogate (TTP or PFS) and the hard endpoint (OS), respectively. 
Gray shaded areas represent the upper and lower limits of the 95% confidence intervals for the 
regression. 
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Figure 4: Correlation between surrogate endpoints PFS and TTP. 
Trial-level correlation between endpoints. R and R2 refers to the weighted Pearson coefficient 
between the HR of PFS and the HR of TTP. Each dot represents one of the phase III clinical trials 
conducted on advanced HCC. Size of the dot is proportional to the total number of patients enrolled 
in the trial. Trials are colored based on whether the final result was positive, negative or non-inferior 
for the primary endpoint (OS). X and Y axis depict the value of the HR for the surrogate TTP and 
PFS, respectively. Gray shaded areas represent the upper and lower limits of the 95% confidence 
intervals for the regression. 
 
Supplementary Figure 1: Correlation between objective response and OS. 
Trial-level correlation between endpoints. R and R2 refers to the weighted Pearson coefficient 
between the HR of OS and the odds ratio of objective response. Each dot represents one of the 
phase III clinical trials conducted on advanced HCC. Size of the dot is proportional to the total 
number of patients enrolled in the trial. Trials are colored based on whether the final result was 
positive, negative or non-inferior for the primary endpoint (OS). X and Y axis depict the value of the 
odds ratio for objective response and the HR for OS, respectively. Gray shaded areas represent the 
upper and lower limits of the 95% confidence intervals for the regression. 
 
 
Tables 
 
Table 1: Phase III trials in advanced hepatocellular carcinoma conducted in the last decade. 
Table 2: Studies analyzing associations between radiological response and survival in 
hepatocellular carcinoma. 
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Summary 
Hepatocellular carcinoma (HCC) is a relevant cause of cancer-related mortality worldwide. 
Around half of HCC patients will receive systemic therapies during their life span. The pivotal 
positive sorafenib trial and regulatory approval in 2007 was followed by a decade of negative 
studies with drugs leading to marginal anti-tumoral efficacy, toxicity, or trials with lack of enrichment 
strategies. This trend has changed during the period 2016-18, when several compounds such as 
lenvatinib (in first line) and regorafenib, cabozantinib, ramucirumab and nivolumab (in second-line) 
showed clinical benefit. These successes came at a cost of increasing the complexity of decision-
making, and ultimately, impacting the design of future clinical trials. Nowadays, life expectancy with 
single active agents has surpassed the threshold of 1 year and the field is facing encouraging 
outcomes ~2 years with sequential strategies. Overall survival (OS) remains as the main endpoint in 
phase III investigations, but as in other solid tumors, there is a clear need to define surrogate 
endpoints that both reliably recapitulate survival benefits and can be assessed prior additional 
efficacious drugs are administered. A thorough analysis of 21 phase III trials published in advanced 
HCC demonstrated a moderate correlation between progression-free survival (PFS) or time to 
progression (TTP) with OS (R=0.84 and R=0.83, respectively). Nonetheless, significant differences 
in PFS were only followed by differences in survival in 3 out of 7 phase III studies. In these later 
cases, the magnitude of benefit for PFS was HR ≤ 0.6, and thus this threshold is herein proposed 
as a potential surrogate endpoint of OS in advanced HCC. Conversely, PFS with a HR between 0.6-
0.7, despite significant, was not associated with better survival, and thus these magnitudes are 
considered uncertain surrogates. In the current review, we discuss the reasons for positive or 
negative phase III trials in advanced HCC, and the strengths and limitations of clinical surrogate 
endpoints (PFS, TTP and objective response rate [ORR]) to predict survival.  
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Introduction 
The incidence of hepatocellular carcinoma (HCC) is increasing and will soon surpass one 
million annual cases worldwide[1]. Up to 80% of HCC patients have concomitant liver cirrhosis, 
mainly as result of hepatitis B and C virus infection, alcohol abuse or non-alcoholic steatohepatitis in 
the context of metabolic syndrome[2]. Coexistence of cancer and cirrhosis in HCC is an essential 
hallmark that has shaped clinical trial design in HCC, as encapsulated in the Barcelona Clinic Liver 
Cancer (BCLC) algorithm[3,4]. Only 40% of HCC patients are diagnosed at early stages, when 
potentially curative treatments (i.e. resection, liver transplantation and local ablation) are 
applicable[4]. As disease progresses, transarterial chemoembolization[5] (for intermediate HCC) 
and systemic targeted therapies[6] (for advanced HCC) have shown survival benefits. Since 
sorafenib positive impact in survival[7], at least 10 trials have shown negative results in front-line. In 
the last 2 years, however, numerous systemic agents have demonstrated clinical benefit in the 
context of phase III trials. The fact that six drugs are currently effective and/or approved by the Food 
and Drug Administration (FDA) for the management of advanced HCC poses a challenge for 
assessing novel strategies in this arena in terms of trial design. Overall survival (OS) is an 
unquestionable, unbiased primary endpoint in oncology and in all randomized studies testing 
systemic therapies in first and second line in advanced HCC[7-27]. However, other solid tumors 
have identified surrogate endpoints of survival that led to accelerated and regular approval, notably 
objective response rate (ORR) and progression free survival (PFS)[28,29]. These endpoints are 
aimed to recapitulate survival benefits with the advantage of being assessed prior additional 
efficacious drugs are administered. By thoroughly analyzing the past experience since sorafenib 
approval, we have assessed the correlation between surrogate endpoint such PFS, time to 
progression (TTP) and ORR with clinically meaningful improvements in OS in 21 reported phase III 
studies[7-27]. Based on this analysis and a conservative approach to define surrogates of OS in 
HCC, we propose PFS with a threshold of HR≤ 0.6 as reliable surrogate with solid positive 
predictive value, whereas the threshold of HR=0.6-0.7 -despite leading to positive statistical results- 
is defined as clinically uncertain in terms of capturing true advantages in OS. In addition, we revisit 
the correlation between ORR by mRECIST and OS and define again that ORR is an independent 
predictor of OS at early, intermediate and advanced stages, meaning that responders survive 
significantly longer. Nonetheless, ORR is still a suboptimal tool as surrogate due to the low 
sensitivity in capturing those patients that benefit from a given drug. Ultimately, we envision 
providing a historical perspective of HCC trial design, which are the lessons to be learned, and how 
to maximize clinical trials success in the near future. 
 
Overview of phase III and practice-changing phase II trials reported during the last 10 years  
Current estimates suggest that around 50% of HCC patients will receive systemic therapies 
at one time point or another during their lifespan [2,4,30]. Several trials have tried to show survival 
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benefits of systemic agents in advanced disease, a traditionally challenging setting due to the limit 
efficacy and high toxicity of conventional systemic chemotherapy[16–18,31]. Randomized studies 
also failed to prove any clinical efficacy for anti-estrogen therapies[32]. In 2008, the landmark 
SHARP trial assessing the multi-tyrosine kinase inhibitor sorafenib (VEGFRs, PDGFRs, RAF and 
KIT) was the first to significantly expand survival (hazard ratio (HR) of 0.69) with manageable 
adverse events[7]. Similar efficacy was demonstrated in the phase III trial testing sorafenib in Asian 
patients[8]. These successful results helped established contemporary concepts in trial design that 
have been implemented in phase III trials over the succeeding years (Table 1 and Figure 1)[33]. 
The main concepts implemented in these trials are: a) selection of patients with well-preserved liver 
function (i.e., Child-Pugh A class) to minimize the competing risk of liver failure and death as a 
result of the natural history of cirrhosis; b) restriction of the investigational niches to those stages 
with unmet medical needs such as advanced stage (BCLC C), or intermediate stage (BCLC B) 
progressing after TACE in case of systemic treatments or adjuvant setting after resection/local 
ablation; c) use of OS as the cornerstone primary endpoint to assess efficacy in advanced stages, 
and d) use of critical prognostic factors as tools for stratification prior randomization based upon 
ECOG 0 vs 1, macrovascular invasion, extrahepatic spread, and alpha-fetoprotein (AFP) levels 
(>400 ng/ml). Etiology is not considered a prognostic factor, but needs to be incorporated when 
testing sorafenib, since it has been demonstrated to be a predictor of response for this drug, at the 
same level than absence of extrahepatic spread and low neutrophil-to-lymphocyte ratio[34].  
In this context, new treatment modalities emerged to challenge sorafenib in first-line or 
placebo in second-line. These include brivanib (VEGFRs and FGFRs)[10,19], sunitinib (VEGFRs, 
PDGFRs and KIT)[9], linifanib (VEGFRs and PDGFRs)[11], erlotinib (EGFR) in combination to 
sorafenib[12], everolimus (mTOR)[20], tivantinib (MET)[23], doxorubicin loaded nanoparticles[27] 
and ADI-PEG 20 (arginine deiminase enzyme)[26] (Table 1). All of them had disappointing results 
and it was not until 2016 that the RESORCE study led to the first positive phase III trial in advanced 
HCC for nearly a decade. Regorafenib (VEGFRs, PDGFRs, KIT and Tie2) improved OS compared 
to placebo from 7.8 to 10.6 months in patients who progressed and were tolerant to sorafenib[22]. 
Notably, OS from starting sorafenib follow by regorafenib was 26 months compared to 19 months 
for sorafenib followed by placebo for patients with advanced HCC [35]. Besides regorafenib, other 
phase III clinical trials have recently improved OS in second-line when compared to placebo: The 
CELESTIAL study, showing median OS of 10.2 months with cabozantinib  (VEGFRs, MET and 
AXL) vs 8 months with placebo[24]; and the REACH-2 study, where ramucirumab (VEGFR2 
monoclonal antibody) provided a median OS of 8.5 months in patients with AFP equal or higher 
than 400 ng/ml vs 7.3 months with placebo[21,25]. AFP is well-known for its independent prognostic 
capacity in HCC[36]. As such, REACH-2 becomes the first positive phase III trial in a biomarker-
driven population of HCC patients. In parallel, lenvatinib (VEGFRs, FGFRs, RET, KIT and 
PDGFRA) has become an option in frontline after the positive result of the non-inferiority REFLECT 
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study[13]. In contrast, three phase III trials testing internal radiation with Y-90 for advanced HCC, 
either as single treatment [SARAH[14] and SIRveNIB[15]] or in combination Y-90 plus sorafenib[37] 
did not meet the primary endpoint of improved OS compared to sorafenib. As a result, Y-90 is 
discouraged for the management of advanced HCC in the recent EASL guidelines[4]. 
Finally, the FDA has granted accelerated approval to the immune checkpoint inhibitor 
nivolumab (monoclonal antibody against PD1) in second-line after a large phase II single-arm trial 
showing promising ORR of 14% by RECIST (responses lasting more than 12 months in 55% of 
cases)[38,39]. Pembrolizumab has recently shown an ORR of 17% and median OS of 12.9 months 
in the second-line setting[40]. The revolution of immune therapies that has changed the paradigm of 
treatment in oncology is now finding its way in HCC, with ongoing phase III in both first- 
(NCT02576509, NCT03298451, NCT03434379, NCT03713593) and second-line (NCT02702401) 
targeting key mediators of the anti-cancer immune response (e.g., PD1, PDL1, CTLA4, LAG3). 
Overall, these successful results have amplified the number of effective drugs available to clinicians 
for the management of advanced HCC (Figure 2). New studies will be crucial to ascertain the most 
efficient way to utilize these drugs and maximize clinical benefit. 
 
Reasons for positive/negative results in phase III investigations 
 
Negative phase III clinical trials 
Until 2016, sorafenib was the only systemic agent able to significantly increase survival in 
patients with advanced HCC[7]. This was despite numerous attempts to improve, or parallel (i.e., 
non-inferiority trials), its efficacy and develop new second-line therapies in the context of phase III 
trials (Table 1). Until then none of the 8 randomized clinical trials (RCTs) testing systemic 
treatments (vs sorafenib in front line[9–12,17] or placebo in second-line[19–21]) was able to achieve 
positive results. Nowadays, 6 of 21 (29%) trials have been able to meet the primary endpoint and 
potentially change the standard of care. This success rate is lower than in other tumor types, with 
reported success rate of 37%[41], and resonates with the difficulties of developing effective drugs in 
HCC. Negative HCC trials enrolled a total of 8,604 patients and consumed a significant amount of 
resources. Failed drugs include linifanib[11], erlotinib[12], brivanib[10,19], sunitinib[9], 
doxorubicin[17,27], everolimus[20], tivantinib[23], ADI-PEG 20[26] and radioembolization with Y-
90[14,15] (Table 1). These drugs have different molecular targets, mechanisms of action, and 
include various treatment modalities (pharmacological vs radiation-based). Thus, it is likely that 
multiple reasons contributed to their failure, but we will dissect three key factors, reviewed in [42]: a) 
limited anti-tumoral efficacy (or biological activity), b) significant toxicity, and c) lack of effective 
enrichment strategies for patient enrollment.  
Limited anti-tumoral efficacy (or biological activity) 
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The first factor relates to limited anti-tumoral activity of the drug as per its main molecular 
targets. This implies that either they have a marginal role in HCC progression, or their selective 
inhibition is insufficient to induce a significant clinical benefit. For instance, evidence from murine 
models demonstrated how aberrant activation of MTOR signaling promotes liver cancer[43], and 
how its selective abrogation has anti-tumoral effects in xenografts[44]. In human HCC, MTOR 
pathway is deregulated in up to 45% of samples[44,45], and yet, the phase III trial testing 
everolimus was unable to improve survival compared to placebo in second line with a HR for OS of 
1.05[20]. Data in phase II already suggested a modest median survival of 8.4 months[46] 
associated to marginal response rates. Also, the companion biomarker study for the phase III trial 
failed to find any robust predictive biomarker of response to everolimus[47]. Altogether, these data 
suggest that MTOR inhibition has no anti-tumoral activity in advanced HCC. Other drugs potentially 
falling under this category include the EGFR inhibitor erlotinib[12], and the FGFR2/VEGFR inhibitor 
brivanib[10,19]. Limited efficacy can also be claimed for Y-90 resin microsphere treatment as a 
superior alternative to sorafenib. The phase III trials reported[14,15], were negative with a HR for 
OS of 1.1. It is important to note that failure to demonstrate superiority does not mean similar 
efficacy, which requires an ad hoc trial design for non-inferiority or equivalence, a concept that will 
be further discussed in this review[48].  
Drug toxicity 
The second reason is significant drug toxicity, which is relevant in cirrhotic patients since 
liver dysfunction decreases the threshold for severe adverse effects. The best example is 
sunitinib[49], that despite having a molecular target profile similar to sorafenib, it was unable to 
improve survival when compared in frontline[9]. The trial was prematurely terminated due to futility 
and safety concerns affecting sunitinib. Median OS for sunitinib was 7.9 months, compared to the 
10.2 with sorafenib (HR of 1.3). Treatment-related deaths occurred in 3.2% and 0.4% of patients 
receiving sunitinib and sorafenib, respectively. When this trial was conducted, sunitinib was already 
FDA approved for advanced kidney cancer and gastrointestinal stromal tumors, where toxicity was 
not a major clinical issue. However, in patients with underlying liver disease the toxicity of sunitinib 
was severe enough to obscure any beneficial anti-tumoral efficacy. Sunitinib has a higher inhibitory 
potency than sorafenib, particularly regarding its anti-angiogenic activity via VEGFR and PDGFR 
Inhibition[50]. Angiogenesis is critical during liver fibrogenesis[51], so the strong and sustained anti-
angiogenic effect achieved with sunitinib seems detrimental, favoring liver failure. Previous phase II 
trials testing sunitinib in HCC offer additional insights into the hepatic toxicity of this drug[52–54], 
including up to 4/37 (11%) treatment-related deaths[54]. An adequate identification of toxicity 
signals at this stage could help mitigate this problem. Another example is the VEGFR/PDGFR 
inhibitor linifanib, tested in frontline versus sorafenib[11]. This trial was early terminated based on 
futility (median OS for linifanib and sorafenib were 9.1 and 9.8 months), but grade 3-4 adverse 
events were significantly more frequent in linifanib than in sorafenib, including hypertension (21% vs 
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11%) and hepatic encephalopathy (7% vs 3%). Besides the negative effect of toxicity in clinical 
outcomes, there is a subtler effect of non-lethal toxicity as it associates with dose reductions, which 
could also decrease antitumor potency.  
Lack of trial enrichment strategies 
A third reason for clinical trial failure is lack of effective enrichment strategies for patient 
enrollment based on predicted biomarkers of response. Trial enrichment in oncology is closely 
linked to the concept of oncogene addiction. This term describes those molecular alterations, 
generally DNA mutations or chromosomal aberrations, required for cancer cell proliferation and 
survival[55]. There are numerous examples in oncology of survival benefits after a clinical trial 
testing a drug only in those patients with mutations in its target[56] (e.g., ALK rearrangements in 
lung cancer and response to crizotinib[57]). Only 2/21 (10%) phase III trials in advanced HCC 
incorporated patient enrichment, likely due to: a) limited access to tumor tissue in patients already 
diagnosed by noninvasive criteria; and b) few druggable targets among the most common genetic 
alterations in HCC[58,59]. In fact, the most common mutations in HCC (TERT promoter, CTNNB1, 
TP53, AXIN1, ARID1A and ARID1B) are untargetable[2,60]. One of them evaluated tivantinib 
versus placebo in second line in patients with high expression of MET assessed with 
immunohistochemistry[23]. This trial was based on a post-hoc analysis of 37 patients from a 
previous phase 2 trial[61] and failed to meet its primary endpoint with a HR for OS of 0.97. 
Arguably, the signal in the phase 2 trial was weak, but most important, recent data questions the 
specificity of tivantinib as a MET inhibitor[62]. It was also thought that MET was a prognostic factor, 
but the median survival of 9.1 months for the placebo arm in MET-high patients in second-line 
challenges this concept[23]. The second trial tested the VEGFR2 monoclonal antibody ramucirumab 
versus placebo in second line (i.e. REACH-2) in patients with AFP higher than 400 ng/mL, and 
showed a significant improvement in OS versus placebo (HR of 0.71[25]). A difference with the 
tivantinib case is that the rationale for REACH-2 came from a post hoc analysis of the negative 
phase III trial in all-comers (i.e., REACH[21]) which enrolled 565 patients. This showed a robust p of 
interaction favoring ramucirumab in patients with high AFP of 0.02. AFP is a well-known poor 
prognostic marker[36,47], highly expressed in tumors with a supposed progenitor cell origin[63], but 
it does not provide a neat link between any specific driver oncogenic event (i.e., structural DNA 
alteration or signaling pathway) and ramucirumab’s main molecular target. Experimental evidence 
identifies VEGFR2 as a marker of hepatic progenitors[64], which could hypothetically explain the 
efficacy of ramucirumab in tumors with high AFP.  
 
Positive phase III clinical trials 
Successful drugs in frontline include sorafenib and lenvatinib, whereas regorafenib, 
cabozantinib, and ramucirumab in patients with high AFP demonstrated efficacy in second line 
(Table 1 and Figure 2). The PD1 inhibitor nivolumab has shown promising results in phase II with an 
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ORR of 14% by RECIST (18% by mRECIST) and a median OS of 15.6 months [38,65], which 
granted its accelerated approval by the FDA. Another immune-based therapy -pembrolizumab- 
reported similar ORR (17%) but lower median OS (12.9 months[40]). Data from phase III trials in 
first-line (nivolumab vs sorafenib) and in second-line (pembrolizumab vs placebo) will be critical to 
fully recommend these immune-based therapies in clinical practice guidelines[4]. Since the strength 
of evidence so far comes from phase II data, current EASL guidelines just posed a weak 
recommendation for nivolumab[4].  
The reasons for trial failure provide the best clues for the qualities of a drug to be successful 
in HCC, which essentially are: a) adequate clinical trial design with an emphasis on selection criteria 
and robust endpoints; b) a fine balance between drug efficacy and toxicity; and c) a proper 
interpretation of efficacy and toxicity signals in phase II trials. Sorafenib epitomizes these qualities, 
and to certain extent, the design principles implemented in the pivotal SHARP trial[7] were adopted 
as best-practices for design in subsequent studies[33]. The target population must include patients 
with well-preserved liver function (i.e., Child-Pugh A with compensated liver disease) to avoid 
competing risks from deaths due to progression of the liver disease, and to minimize drug toxicity. 
Also, patients need to be fit enough to tolerate the drug and with a life expectancy of at least 3 
months, which can be reasonably guaranteed by enrolling patients with ECOG performance status 
test (PST) of 0-1. It is paramount to enroll patients at the same clinical stage as per the BCLC 
classification[4,66]. The SHARP trial was instrumental to eradicate the misleading concept of 
‘unresectable’ HCC when conducting HCC trials. This concept included a heterogeneous population 
of patients at intermediate (BCLC-B) and advanced (BCLC-B) stages[67], which imposed significant 
bias when interpreting trial results. In addition to the same clinical stage, patients need to be 
adequately stratified for known HCC prognostic factors and geographic region. 
Regarding patient’s selection, the success of the REACH-2 trial underscores the importance 
of properly interpreting post hoc analysis. The pooled analysis of REACH and REACH-2 assessing 
ramucirumab in those patients with AFP > 400 ng/mL further confirms a significant and clinically 
meaningful benefit of ramucirumab vs placebo in second-line (median survival 8.1 vs 5 months; 
HR=0.694)[25]. The rationale to enrich trials based on predicted oncogene addiction is two-fold: 
first, to maximize anti-tumoral response by perturbing the cancer drivers active in a given patient, 
and second, to spare unnecessary toxicity in those patients without the oncogene addiction. HCC 
has few druggable targets among the most frequent driver mutations, but a recent proof-of-concept 
trial reinforces the validity of this approach to explore treatment response[68]. A screening of 1,318 
HCC patients allowed enrolling 54 cases with RAS mutations (4.4%) detected using circulating 
tumor DNA (ctDNA) in a phase II trial testing the combination of sorafenib with the MEK inhibitor 
refametinib[68]. Mutation analysis of ctDNA is feasible in HCC[69] and facilitates screening of large 
populations. Other potential druggable oncogenic alterations in HCC include high-level DNA 
amplifications of FGF19[70,71] or VEGFA[70,72]. Phase II clinical trials are currently exploring 
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selective inhibition of these candidate oncogene addition loops[73]. There is also increasing interest 
in developing biomarkers to identify the 20% of patients who respond to immune-based therapies, 
who show outstanding OS. The use of PD-L1 staining seems irrelevant in HCC[38], and other 
potential biomarkers such as tumor mutational burden (TMB)[74] or the HCC immune class[75] are 
under investigation. To facilitate the implementation of biomarker-based clinical trials in HCC, it is 
essential to enforce mandatory tissue collection in all clinical trials testing new compounds[4]. In this 
regard, the impact of intratumor heterogeneity in single-biopsy predictions is still debated despite 
recent studies have shown that driver gene mutations are common between different regions of the 
tumor[76,77]. 
Traditionally, new therapies were compared with standard of care or placebo to demonstrate 
greater efficacy of the new drug. Despite this is the recommended trial design practice in 
HCC[4,33], some studies after SHARP used non-inferiority designs to challenge sorafenib in first-
line. The hypothesis in non-inferiority trials is that the new compound is not substantially worse than 
the current standard, as opposed to equivalence trials, which are designed to demonstrate that the 
experimental treatment is neither worse not better than the standard therapy[78]. Non-inferiority 
trials are required to claim similar efficacy as opposed to assuming it from a negative superiority 
trial, as previously explained for the Y-90 trials. The non-inferiority trial scenario in HCC is 
extensively described elsewhere[42], and caveats include the need for larger sample sizes and a 
very small window of opportunity, as defined by the tight non-inferiority margins. For instance, the 
BRISK-FL trial was designed to demonstrate non-inferiority of brivanib compared to sorafenib in first 
line[10]. The trial assumptions set the upper limit of the 95% confidence interval of HR for OS to 
1.08. To call non-inferiority, the HR could cross 1, but the upper boundary needed to fall between 1 
and 1.08. This threshold is very stringent and can be interpreted as the requirement to demonstrate 
a robust non-significant trend towards superiority for the new drug. The value proposed by FDA has 
been calculated based upon capturing at least >60% of the survival benefit obtained with 
sorafenib[13]. The BRISK-FL trial did not meet this endpoint since the HR confidence interval limits 
for OS were 0.94 and 1.23. The concept of non-inferiority trials introduces other considerations in 
treatment recommendations such as toxicity or cost, which will surely contribute to frame the 
landscape of systemic therapies in HCC.  
 
Hard and surrogate endpoints: Implications in clinical trial design  
The overreaching goal of oncological treatments is to allow patients to live longer and better 
lives than they would do without treatment[79]. Thus, clinical research needs to unequivocally 
demonstrate statistically and clinically meaningful improvements of the experimental arm over the 
standard of care. Three types of endpoints have been defined: 1. Hard endpoints, such as overall 
survival and cancer-specific survival; 2. Surrogate endpoints such as PFS, TTP and ORR, and 3. 
Patient reported endpoints, such as quality of life (QOL).  
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Overall survival 
This hard endpoint quantifies the time between random trial allocation and death, whatever 
the cause. Since is not subject to investigator bias, OS has been traditionally recommended by 
international HCC guidelines as the primary endpoint for randomized phase III trials testing new 
therapies[80]. In fact, all regular FDA drug approvals in advanced HCC were based upon 
improvements in OS [7,22]. Cancer-specific survival, where only deaths due to cancer are 
considered and noncancer-related deaths are censored, is more difficult to assess in conventional 
trial settings. Deaths due to competing risks, such as liver failure, require a subjective interpretation 
by the investigator, and thus are more prone to bias[33]. 
What is the magnitude of benefit to define it as clinically meaningful? This is a controversial 
topic, highly dependent on the expected outcome for the target population, with confronted opinions 
between patients, providers, regulatory agencies and health insurers [81,82]. In HCC, there is no 
consensus on what absolute survival benefit (or the magnitude of benefit in OS as per HR) to be 
defined as clinically relevant. Reported thresholds of OS with HR<0.8 are also sound for capturing 
the benefit of patients in advanced HCC trials[83]. An unwritten rule among experts estimate that in 
advanced HCC scenario, where natural outcome (placebo arm) is estimated to be of around 8 
months, absolute gains beyond 2 months are considered clinically relevant, while those below 1 
months are not.   
Survival has some limitations as a sole endpoint in cancer research. First, it might require a 
long follow-up time to capture enough events due to significant improvement in median OS in the 
experimental arm[35]. This negatively impacts feasibility and delays access to patients to highly 
effective drugs. Second, it can be affected by sequential therapies received after tumor progression 
(post-progression survival), such as for instance regorafenib after a first-line therapy. This might 
involve one third of patients in recent phase III trials[13]. In this context, validation of surrogate 
endpoints of OS is paramount to facilitate trial execution and favor a quick deployment of effective 
drugs in routine clinical conditions. 
 
Surrogate endpoints: PFS, TTP and ORR 
Ideally, significant improvement in OS is preferred, but many drugs have been approved 
based on their ability to improve other less robust endpoints, termed surrogates (i.e., TTP, PFS and 
ORR). These are outcomes not inherently meaningful from the clinical standpoint, but thought to 
accurately predict hard outcomes such as OS[84]. The development of surrogate endpoints became 
a necessity in clinical trials in cardiology, where the long time to accumulate enough events for a 
hard endpoint made most studies unfeasible. Use of surrogate endpoints is becoming a need in 
oncology where effective post-progression therapies are available.  
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Accelerated approval based upon surrogate endpoints is becoming the most relevant path 
for cancer drug regulatory approval in the US. Between 2009 and 2014; the FDA approved 83 drugs 
in oncology, 66% of them on the basis of surrogate endpoints[85]. The FDA’s accelerated approval 
program was introduced in 1992 as a social compromise during the worse years of the HIV 
epidemic to expedite access to agents for life-threating conditions based on surrogate endpoints. 
The program included a “safety net” that required the manufacturer to conduct post-marketing 
studies and confirm the efficacy of the drug using hard endpoints[86]. A recent analysis of approved 
drugs during the period 1992-2017 led to the following conclusions[28]: a) Accelerated approval was 
granted for 93 indications, ORR being the most common surrogate endpoint used (87% of cases), 
b) Among drugs approved through this path, 55% were ultimately confirmed for regular approval, 
5% of indications were withdrawn (e.g., bevacizumab in metastatic breast cancer[87]), whereas in 
others the process has not been concluded. 
Despite the increasing importance of surrogate endpoints in oncology, they have two main 
limitations. First, since they usually rely on the radiological definition of tumor progression or 
response, they are vulnerable to interpretation bias. This can be minimized by using central 
radiology reviews and a designated adjudicator of response. Second, and more important, in order 
to be reliable, they require validation as credible predictors of OS[84]. Validation of surrogate 
endpoints can be conducted at the individual- or trial-levels[88]. While validation of individual-level 
surrogacy requires individual patient data from at least one clinical trial, trial-level surrogacy uses 
assembled data from multiple trials. The Institute for Quality and Efficiency in Health Care has 
proposed a set of criteria to quantify the association between a surrogate and hard endpoint, which 
includes low (R<0.7), moderate (R>0.7 to R<0.85) and high correlation (R>0.85)[89]. R refers to the 
weighted Pearson coefficient between HR of OS and HR of the surrogate endpoint. Alternative 
methods to study this correlation have been reported[90]. A systematic review and meta-analysis of 
trial-level surrogate endpoints (PFS, TTP and ORR) for OS in oncology including 36 articles and 
352 clinical trials found low, moderate and high correlation with OS in 52%, 25% and 23% of 
surrogate endpoints, respectively[84]. 
In order to explore the concept of surrogate endpoints recapitulating OS in advanced HCC 
we have identified 21 RCTs assessing systemic therapies with or without loco-regional therapies in 
advanced HCC (12 in first-line and 9 in second-line) (Table 1) published between 2008 and 2018 
through a MEDLINE search via PubMed using the keywords “advanced hepatocellular carcinoma”. 
Results were limited to “clinical trial, phase III”. Trials recently presented at international meetings 
(2016-2018) were also included despite the full manuscript is not yet available. For each trial, data 
on sample size, radiological response, TTP and OS were collected. TTP and OS were determined 
in terms of hazard ratio (HR) using published data (values less than 1 denotes a favourable result in 
the experimental group). In addition, ORR was established with odds ratio calculated from the 
published radiological response (values greater than 1 denotes a favourable result in the 
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experimental group). For the purpose of the trial-level analysis, we first assessed the overall 
correlation between PFS and OS (R=0.84; R2=0.71) (Figure 3A), and then the correlation of TTP 
and OS (R=0.83; R2=0.69) (Figure 3B). Afterwards, we established a conservative threshold of 
positive predictive value for PFS since this is the most documented surrogate time-to-event 
endpoint in oncology, and the one showing a higher correlation with OS[84]. Finally, we explored 
the correlation between ORR assessed as per mRECIST and survival in early, intermediate and 
advanced HCC.  
 
Progression-free survival 
PFS is a composite endpoint of two variables: death and evidence of radiological 
progression, usually defined by standard criteria as RECIST[91] or mRECIST[92]. International 
guidelines initially discouraged this endpoint in HCC due to the competing risk of dying due to 
progressed liver dysfunction despite a relevant anti-tumoral benefit[33]. However, this limitation has 
been mitigated since most trials in HCC have adopted restrictive inclusion criteria in terms of liver 
function (i.e., Child-Pugh A without decompensation). In this scenario, the likelihood of death as a 
result of liver decompensation (i.e., gastrointestinal bleeding, encephalopathy or ascites and 
spontaneous peritonitis) is 5% at one year[93]. When we evaluate the association between PFS and 
OS in HCC phase III trials, we observe a moderate Pearson correlation (R) of 0.84 (Figure 3A). This 
figure falls in the upper boundary of a moderate correlation (R between 0.7 and 0.85). When 
specifically analyzing the positive predictive value of theoretical thresholds of PFS correlating with 
OS, only 3/7 PFS reported a HR ≤0.6 that was significantly associated with a positive survival 
clinical benefit (in all cases with a HR for OS < 0.8). Conversely, those four studies reporting a 
positive PFS with a HR between 0.6-0.8 were associated with no significant survival benefits (HR 
for OS between 0.87 and 1.05) (Figure 3A). In our study, according to the linear regression equation 
obtained [log HROS = 0.072 + 0.487 x log HRPFS], a threshold of PFS HR=0.6 (representing a 40% 
risk reduction) will decrease ~17% the risk of OS (OS HR=0.83) (see Figure 3A). In summary, a 
moderate correlation has been established between PFS and OS in 21 RCTs in advanced HCC. A 
value of HR ≤0.6 is proposed as surrogate threshold effect [94], and is likely to predict a clinically 
meaningful improvement in OS. Is worth to mention though that this rule is supported mainly by 
positive trials in the second-line setting comparing active drugs vs placebo. We assume that such 
association is retained in front-line comparing two active drugs, but recommendation in that setting 
should be tempered due to the lack of confirmatory data. 
Time to progression 
This endpoint quantifies the time between trial allocation and radiological progression, 
usually defined by standard criteria as RECIST[91] or mRECIST[92]. Deaths are censored as non-
radiological progressions at the time of death or at an earlier visit, with a cause-specific hazard, 
representing informative censoring. Symmetric repeated radiological measurements every 6-8 
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weeks are required to avoid missing moderate differences between treatment groups[33]. This 
recommendation was not followed in the SIRveNIB[15], SARAH[14] and ADI-PEG 20[26] trials. 
To delineate the adequacy of TTP as a surrogate of OS in HCC we conducted also a trial-
level meta-analysis to evaluate the correlation between TTP and OS in 21 RCTs (Figure 3B). The 
Pearson correlation (R) was 0.83, which indicates a moderate association according to the IQWIG 
guidelines[84]. In 10 phase III trials there was a significant difference in TTP in favor of the 
investigational arm. However, these positive results in TTP were not followed by superiority in OS in 
5 (50%) trials. Brivanib[19] and ramucirumab[21] in second-line showed efficacy as per TTP 
(HR=0.56 and 0.59, respectively), while not significantly improving the hard endpoint of OS 
(HR=0.89 and 0.87, respectively). Lenvatinib[13] in first-line versus sorafenib also showed 
significant differences in TTP favoring lenvatinib (HR 0.63), without showing superiority for OS 
(HR=0.92). This trial was positive since it was designed for non-inferiority (upper 95% CI lower than 
1.08). Finally, linifanib[11] and hepatic infusion arterial chemotherapy (HAIC)[18] in first-line failed to 
show any benefit in terms of OS (HR=1.05 and 1.01, respectively) even though there was a clear 
benefit when measuring TTP (HR=0.76 and 0.65, respectively). These results do not support the 
initial recommendation after the SHARP trial of using TTP as the optimal surrogate endpoint[33] in 
phase 2 trials, and reinforce the need for accurate evaluation of surrogacy in clinical trials. Based on 
the linear regression model obtained [log HROS = 0.083 + 0.491 x log HRTTP], we can extrapolate 
that a therapy producing a 40% risk reduction in TTP will yield an estimated ~16% risk reduction in 
OS (HR=0.84) (see Figure 3B). Moreover, in order to directly compare the performance of PFS and 
TTP, we analyzed the correlation between both surrogate endpoints, obtaining a Pearson 
correlation (R) of 0.99 (Figure 4). Thus, in the modern era of HCC trial design, with minimal 
cirrhosis-related deaths (due to the inclusion of Child-Pugh A), there is a strong correlation between 
both endpoints. In fact, when we inferred the non-reported PFS HR of SHARP and AP trials 
according to the linear equation obtained comparing both surrogate endpoints [log HRPFS = 0.014 + 
0.927 x log HRTTP], the HRs values are close to 0.60, just at the previously proposed minimum 
threshold. 
There are two other considerations regarding this endpoint. First, not all types of tumor 
progression may have the same clinical meaning. Recent data also suggest that TTP may capture 
heterogeneous features, with essentially two types of progression at advanced stages[95,96]. In 
particular, survival after progression is significantly worse for patients who develop a new 
extrahepatic lesion and/or vascular invasion (median OS = 7.1 months) compared to those who 
progress due to the growth of existing intrahepatic/extrahepatic lesions or the development of a new 
intrahepatic lesion (median OS = 14.9 months). Second, factors including evaluation bias, trial 
attrition or informative censoring may weaken the association between the TTP and OS [29]. 
Finally, prolonged exposure to a given therapy might lead to a phenotypic change in tumors, thus, 
offsetting any initial advantage from the treatment captured by the surrogate endpoint[97].  
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Objective response rate 
Tumor response in oncology trials is typically measured using the Response Evaluation 
Criteria in Solid Tumors (RECIST)[91]. These criteria standardize methods for converting 
radiological observations into a quantitative and statistically tractable framework to define tumor 
response (i.e., a 30% decrease in the diameter of target lesion). ORR is the percentage of patients 
who achieve an objective tumor response. Disease control rate (DCR) is the combination of ORR 
and stable disease, but it has two disadvantages that limit its adoption for regulatory approval: a) 
the definition of duration of stable disease varies between studies; and b) stable disease can reflect 
inherent characteristics of the tumor rather than treatment efficacy. 
The RECIST criteria were originally developed to evaluate cytotoxic agents. The 
generalization of targeted therapies has challenged this simplistic approach that relies on tumor 
shrinkage to indicate clinical efficacy. Sorafenib was associated with only 2-3% of ORR, despite 
providing clear survival benefits[7,8]. Given the poor correlation between tumor response assessed 
with conventional tools and OS, a group of experts convened by the American Association for the 
Study of Liver Diseases (AASLD) proposed specific amendments to standard RECIST[33]. Further 
description of response and progression resulted in the criteria named modified RECIST 
(mRECIST), which ultimately incorporates the concept of viable tumor defined as the portions of 
tumor showing arterial enhancement[92]. The mRECIST criteria in HCC have improved the 
sensitivity to quantify tumor response with targeted therapies: ORR of 9-17% with 
sorafenib[10,13,18], 10-12% with brivanib[10,19], 11% with regorafenib[22] and 24% with 
lenvatinib[13]. Retrospective studies have consistently demonstrated that patients who achieved an 
objective response on sorafenib had a longer survival than non-responders[98–100]. Recently, data 
from double-blind randomized trials assessing brivanib and nintedanib further validated this 
association [101,102]. Thus, the association between tumor response and improved OS in HCC 
patients at advanced stages complement what was already knew in patients at early and 
intermediate stages treated with loco-regional therapies[103–109](Table 2).  
When we evaluate the trial-level correlation between ORR and OS (Supplementary Figure 
1), the R weighted Pearson coefficient obtained is 0.54. This is significantly lower than the 
correlation obtained with PFS/TTP and OS as depicted in Figure 3. There are two reasons for this: 
one is inherent to the use of odds ratio instead of hazard ratio to compare differences in ORR. The 
accuracy of odds ratio decreases for low values of ORRs. The second reason is that only a small 
proportion of patients within these trials achieved ORR (~10-20%), which is, in fact, the event that 
correlates with better survival[101]. A direct comparison between RECIST and mRECIST for OS 
surrogacy through an independent meta-analysis of trials using either criteria would be ideal to 
define the role of ORR to predict OS in advanced HCC. This will also help determine the best tool to 
evaluate tumor response to systemic therapies. However, since only 5 RCTs reported response 
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data using mRECIST, we did not sub-analyze this endpoint according to the tool used to evaluate 
response. 
Some other questions remain unanswered. As observed in other solid tumors treated with 
efficacious targeted therapies[110–112], the reported rates of responders are still suboptimal to 
estimate the maximum number of patients who would benefit from the treatment. In addition, the 
duration of response might be more clinically relevant than the extent of tumor reduction. Finally, the 
strategy to evaluate response might require a thoughtful revision when assessing immunotherapies. 
As shown in melanoma patients treated with checkpoint inhibitors, standard RECIST may not 
provide a reliable assessment of antitumor efficacy[113]. In fact, response to immunotherapy may 
take longer compared to other agents and can even falsely mirror criteria for progression (i.e., 
pseudo-progression)[114]. Immune-related response criteria have been developed[115,116], 
including the concept of “confirmation of progression” by a second scan obtained at least 4 weeks 
after progressive disease has been registered. 
Despite all the challenges that evaluation of tumor response face in oncology, and 
particularly in HCC, the importance of ORR as a surrogate endpoint is recognized by regulatory 
agencies and frequently used for accelerated drug approval. This was the case of nivolumab, 
approved in second-line based on an ORR of 18% by mRECIST and 14% by RECIST [38,39]. 
Remarkably, objective response to nivolumab has been associated with prolonged OS[65]. Overall, 
the fact that a high ORR in phase II trials was considered a robust criterion for drug approval[117], 
and further success in phase III trials[118], indicates that ORR should be considered as a primary 
endpoint for single-arm phase II studies. Related to this, early clinical trials are showing promising 
results with combinations of checkpoint inhibitors and targeted therapies, as measured by ORR. 
Lenvatinib plus pembrolizumab[119] and atezolizumab plus bevacizumab[120] achieved an ORR of 
46% by mRECIST and 50% by RECIST in advanced HCC, respectively. As a result, the later 
combination was granted breakthrough therapy designation by the FDA[121]. Of note, most of the 
drugs approved under the accelerated program reported ORR exceeding 30%[122]. 
 
Patient-reported endpoints: Quality of life 
Health-related QOL measures the effect of the disease on an individual’s physical, 
psychological and social functioning and well-being[123]. Regulatory agencies recognize 
symptomatic improvement as a direct clinical benefit to patients and an important consideration in 
drug approval[124]. However, unlike OS, the interpretation of QOL is subjective. In HCC, two tools 
have been proposed to measure QOL: the European Organization for Research and Treatment of 
Cancer Quality of Live Questionnaire (EORTC QLQ-HCC18)[125] and the Functional Assessment 
of Cancer Therapy-Hepatobiliary (FACT-Hep) questionnaire[126]. They can be used to evaluate 
time to symptomatic progression (i.e. time between trial allocation and the occurrence of disease 
related symptoms according to preestablished scores). QOL was measured in the SHARP trial[7] 
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according to the FHSI-8 questionnaire[127], a reduced version of FACT-Hep, with results that 
collided with OS. Conversely, the SARAH trial[14] reported better global health status with Y-90 
when compared to sorafenib based on QLQ-HCC18, which was inconsistent with the primary 
endpoint of OS. Evaluation of QOL is contingent on when it was assessed during disease 
progression. Also, significant changes in QOL have been observed across different cultures[128]. 
Defining and evaluating reliable QOL assessment tools has been established as one of the unmet 
needs in HCC research by international guidelines[4]. In summary, health-related QOL measures 
are not ready to support, as single tools, regulatory approval for drugs in HCC. 
 
Conclusions 
The current period of drug development in HCC is providing major advancements in the 
management of this devastating disease. Six drugs have currently shown activity as systemic 
therapies, which represents an unprecedented revolution for the last 50 years. Novel drugs or 
combinations strategies are emerging in the field, and thus new tools will be required for the proper 
assessment of clinical benefits. OS is still the most robust endpoint but the increasing number of 
treatments available in advanced HCC preludes the use of surrogate endpoints, less vulnerable to 
subsequent treatments after progression. In this scenario, PFS has shown moderate correlation 
with OS (R=0.84), and a threshold of HR≤0.6 defines a conservative approach of surrogate 
endpoint able to capture survival differences in a superiority trial with a high positive predictive 
value. Two recent studies have been released supporting our threshold of HR ≤ 0.6 for PFS. The 
first one, an individual-patient data meta-analysis of two RCTs (REACH[21] and REACH-2[25]), 
showing a significant OS HR with a PFS HR of 0.57[129]. The second one, a phase 3 RCT 
comparing sorafenib with or without cTACE in advanced HCC, a negative study for its primary 
endpoint (OS) with a PFS HR of 0.73[130]. Thus, PFS-HR ≤0.6 could be considered a candidate 
endpoint in phase II and phase III RCTs when subsequent therapies are expected to impact overall 
outcome. ORR by sensitive criteria (mRECIST) may be useful particularly in single arm phase II 
trials with proof of concept drugs or in combination studies targeting accelerated approval with a 
threshold >30%. Finally, the current development of RCTs assessing immune therapies or drug 
combinations in HCC will certainly evolve the paradigm of drug development and trial design. 
Particularly of interest will be whether the statements proposed in the present review are confirmed 
in trials designed with composite primary endpoints, such as OS-PFS for lenvatinib+pembrolizumab 
vs lenvatinib (NCT03713593) or OS-ORR for atezolizumab+bevacizumab vs sorafenib 
(NCT03434379). 
Key points 
 
 In the last two years four systemic agents (i.e., regorafenib, lenvatinib, cabozantinib and 
ramucirumab) have shown clinical benefit in the setting of phase III trials and one (i.e., 
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nivolumab) has been granted accelerated approval based on a phase II trial, expanding, thus, 
the pipeline of effective drugs available in advanced HCC to providers. 
 The improvement in the number of effective agents comes at a cost of increased complexity of 
clinical decision-making, and thus, in the design of future clinical trials. 
 OS is still the most robust endpoint in advanced HCC but the increasing number of treatments 
after progression underscore the need for surrogate endpoints. 
 PFS has a moderate correlation at trial level with OS (R=0.84). A conservative minimum 
surrogate threshold effect of HR ≤0.6 is highly predictive of a significant improvement in OS, 
whereas HR ranging from 0.6 – 0.7 are uncertain surrogates. 
 ORR by sensitive criteria in single arm phase II trials could be a useful tool to prioritize 
treatments for testing in phase III trials. 
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Figure legends 
 
Figure 1: Median overall survival of treatment modalities assessed in phase III trials for 
advanced hepatocellular carcinoma.  
Treatments with more than one dot represent all the results obtained from different clinical trials 
testing the same compound. Trials are colored based on whether the final result was positive for 
superiority (green), negative (red) or positive for non-inferiority (orange) for the primary endpoint 
(OS). Placebo appears in blue. Relevant inclusion/exclusion criteria that may impact on median OS 
are: no portal vein invasion [13], no pulmonary metastases [37], sorafenib tolerant [22], MET high 
[23] and AFP>400ng/ml [25].  
 
Figure 2: Treatment strategy for advanced hepatocellular carcinoma. Adapted from Llovet et 
al. Nat Rev Clin Oncol 2018[6].  
Drugs in green have positive results from phase III trials with a superiority design (sorafenib in the 
first-line setting and regorafenib, cabozantinib and ramucirumab in the second-line setting). Drugs in 
orange have positive results from phase III trials with a non-inferiority design (lenvatinib in the first-
line setting). Drugs in red have received accelerated approval from the FDA on the basis of 
promising efficacy results in phase II trials (nivolumab in the second-line setting). Key details of the 
patient populations are provided. AFP: Alpha-fetoprotein; BCLC: Barcelona Clinic Liver Cancer 
(classification); ECOG PS: Eastern Cooperative Oncology Group performance status; EHS: 
extrahepatic spread; HCV: hepatitis C virus; HR: hazard ratio; mRECIST: modified Response 
Evaluation Criteria In Solid Tumors; ORR: objective response rate; OS: overall survival. 
 
Figure 3: Correlation between surrogate endpoints (PFS[A] and TTP[B]) and hard endpoint 
(OS).  
Trial-level correlation between endpoints using criteria from the Institute for Quality and Efficiency in 
Health Care (IQWIG). R and R2 refers to the weighted Pearson coefficient between the HR of OS 
and the HR of the surrogate endpoint. IQWIG categorizes the strength of the correlation based on 
the value of R as low (R<0.7), moderate (R>0.7 to R<0.85) and high (R>0.85)[89]. Each dot 
represents one of the phase III clinical trials conducted on advanced HCC. Size of the dot is 
proportional to the total number of patients enrolled in the trial. Trials are colored based on whether 
the final result was positive, negative or non-inferior for the primary endpoint (OS). X and Y axis 
depict the value of the HR for the surrogate (TTP or PFS) and the hard endpoint (OS), respectively. 
Gray shaded areas represent the upper and lower limits of the 95% confidence intervals for the 
regression. 
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Figure 4: Correlation between surrogate endpoints PFS and TTP. 
Trial-level correlation between endpoints. R and R2 refers to the weighted Pearson coefficient 
between the HR of PFS and the HR of TTP. Each dot represents one of the phase III clinical trials 
conducted on advanced HCC. Size of the dot is proportional to the total number of patients enrolled 
in the trial. Trials are colored based on whether the final result was positive, negative or non-inferior 
for the primary endpoint (OS). X and Y axis depict the value of the HR for the surrogate TTP and 
PFS, respectively. Gray shaded areas represent the upper and lower limits of the 95% confidence 
intervals for the regression. 
 
Supplementary Figure 1: Correlation between objective response and OS. 
Trial-level correlation between endpoints. R and R2 refers to the weighted Pearson coefficient 
between the HR of OS and the odds ratio of objective response. Each dot represents one of the 
phase III clinical trials conducted on advanced HCC. Size of the dot is proportional to the total 
number of patients enrolled in the trial. Trials are colored based on whether the final result was 
positive, negative or non-inferior for the primary endpoint (OS). X and Y axis depict the value of the 
odds ratio for objective response and the HR for OS, respectively. Gray shaded areas represent the 
upper and lower limits of the 95% confidence intervals for the regression. 
 
 
Tables 
 
Table 1: Phase III trials in advanced hepatocellular carcinoma conducted in the last decade. 
Table 2: Studies analyzing associations between radiological response and survival in 
hepatocellular carcinoma. 
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Median HR Median HR Median HR
Sorafenib 299 2.3 5.5 10.7
Placebo 303 0.7 2.8 7.9
Sorafenib 150 3.3 2.8 6.5
Placebo 76 1.3 1.4 4.2
Sunitinib 530 6.6 4.1 3.6 7.9
Sorafenib 544 6.1 3.8 3 10.2
Brivanib 577 12.0 4.2 9.5
Sorafenib 578 8.8 4.1 9.9
Linifanib 514 10.1 5.4 4.2 9.1
Sorafenib 521 6.1 4 2.9 9.8
Sorafenib+Erlotinib 362 6.6 3.2 9.5
Sorafenib 358 3.9 4 8.5
Lenvatinib 478 24.1 8.9 7.4 13.6
Sorafenib 476 9.2 3.7 3.7 12.3
Y90 237 15.2 4.1 8
Sorafenib 222 10.4 3.7 9.9
Y90 182 16.5 6.1 5.8 8.8
Sorafenib 178 1.7 5.4 5.1 10
FOLFOX4 184 8.2 2.93 6.4
Doxorubicin 187 2.7 1.77 4.97
Sorafenib+Doxorubicin 173 NR 3.6 9.3
Sorafenib 173 NR 3.2 10.5
Sorafenib+HAIC 103 36.3 5.3 4.8 11.8
Sorafenib 103 17.5 3.5 3.5 11.5
Brivanib 263 9.9 4.2 9.4
Placebo 132 1.5 2.7 8.2
Everolimus 362 2.2 3 7.6
Placebo 184 1.6 2.6 7.3
Ramucirumab 283 7.1 3.5 2.8 9.2
Placebo 282 0.7 2.6 2.1 7.6
Regorafenib 379 10.6 3.2 3.1 10.6
Placebo 194 4.1 1.5 1.5 7.8
Tivantinib 226 0.0 2.4 2.1 8.4
Placebo 114 0.0 3 2 9.1
Cabozantinib 470 3.8 5.4 5.2 10.2
Placebo 237 0.4 1.9 1.9 8
Ramucirumab 197 4.6 3.02 2.8 8.5
Placebo 95 1.1 1.61 1.6 7.3
ADI-PEG 20 424 NR 2.6 7.8
Placebo 211 NR 2.6 7.4
Doxorubicin Transdrug 263 0.8 2.3 9.1
Placebo 134 0.7 2.3 9
*Radiological evaluation by mRECIST
NR = Non reported
Green = Positive for superiority (p < 0.05)
Orange = Positive for non-inferiority (upper 95% CI < 1.08)
Red = Negative for superiority or non-inferiority
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ReLive (27)
ADI-PEG 20 (26)
REACH-2 (25)
CELESTIAL (24)
METIV-HCC (23)
RESORCE* (22)
REACH (21)
EVOLVE-1 (20)
BRISK-PS* (19)
SILIUS* (18)
CALGB80802 (17)
EACH (16)
SIRveNIB (15)
REFLECT* (13)
SEARCH (12)
LIGHT (11)
BRISK-FL* (10)
SUN1170 (9)
SHARP (7) 0.58 (0.45 - 0.74) 0.69 (0.55 - 0.87)
0.57 (0.42 - 0.79) 0.68 (0.50 - 0.93)Asian-Pacific (8)
Trial Arms N ORR
TTP OS
1.13 (0.98 - 1.31)
1.01 (0.88 - 1.16)
0.76 (0.64 - 0.90)
1.14 (0.94 - 1.37)
PFS
1.30 (1.13 - 1.50)
1.07 (0.94 - 1.23)
1.05 (0.90 - 1.22)
0.93 (0.78 - 1.11)
0.88 (0.7 - 1.1)
0.65 (0.48 - 0.87)
1.13 (0.99 - 1.30)
0.81 (0.70 - 0.95)
1.11 (0.94 - 1.31)
0.66 (0.57 - 0.77)0.63 (0.53 - 0.73)
NR
0.92 (0.79 - 1.06)
0.89 (0.69 - 1.15)
1.05 (0.86 - 1.27)
1.03 (0.85 - 1.25)
0.89 (0.70 - 1.10)
0.62 (0.49 - 0.79)
0.90 (0.72 - 1.20)
0.75 (0.57 - 1.00)
1.15 (0.94 - 1.41)
1.10 (0.90 - 1.40)
0.80 (0.63 - 1.02)
1.06 (0.80 - 1.40)
1.01 (0.74 - 1.37)
0.95 (0.74 - 1.22)
0.56 (0.42 - 0.76)
0.93 (0.75 - 1.15)
0.59 (0.49 - 0.72)
0.44 (0.36 - 0.55)
0.96 (0.74 - 1.25)
0.41 (0.34 - 0.49)
0.43 (0.31 - 0.58)
NR
NR
0.46 (0.37 - 0.56)
0.96 (0.75 - 1.22)
0.44 (0.36 - 0.52)
0.45 (0.34 - 0.60)
1.18 (0.96 - 1.43)
1.00 (0.78 - 1.28)
NR
NR
NR
NR
NR
NR
NR
NR
0.87 (0.72 - 1.05)
0.63 (0.50 - 0.79)
0.97 (0.75 - 1.25)
0.76 (0.63 - 0.92)
0.71 (0.53 - 0.95)
1.02 (0.85 - 1.23)
0.63 (0.52 - 0.75)
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Treatment Study N
Radiological       
response
Median OS (HR/OR OS)             
[R vs Non-R]
Prediction 
of OS
RFA Cabibbo G et al (retrospective RFA)* (103) 151 CRR=78% 59.4m vs 26m (HR=0.3) Yes (UV)
RFA/PEI Sala et al (retrospective)* (105) 282 CRR=68% 43m vs 28m (OR=0.58) Yes (MV)
TAE/TACE Gillmore R et al (retrospective) (106) 83 ORR=57% 20.7m vs 13.3m (HR=0.58) Yes (MV)
TACE Kim BK et al (retrospective) (107) 292 ORR=71.9% 33.8m vs 17.1m (HR=0.48) Yes (MV)
TACE Jung ES et al (retrospective) (108) 114 ORR=63.3% 41.1m vs 20.7m (HR=0.31) Yes (MV)
DEB TACE Prajapati HJ et al (retrospective) (109) 120 ORR=52.5% 28m vs 9.1m (HR=0.4) Yes (MV)
Sorafenib Edeline J et al (retrospective) (98) 53 ORR=23% 18.2m vs 7.7m (NR) Yes (UV)
Sorafenib Ronot M (retrospective)** (99) 82 ORR=28% 25.5m vs 5.7m (HR=0.19) Yes (MV)
Sorafenib Takada J (retrospective) (100) 191 ORR=13.1% ≈21m vs ≈10m (NR) Yes (UV)
Brivanib Lencioni R et al (phase III trial) (101) 226 ORR=11.5% 14.3m vs 9.4m (HR=0.48) Yes (MV)
Nintedanib Meyer T et al (2 phase II trials) (102) 180 ORR=15.6% 16.7m vs 10.9m (HR=0.62) Yes (MV)
Nivolumab El-Khoueiry A et al (phase II trial)*** (65) 145 ORR=14% Non-reached vs 13.4m^ (NR) Yes (UV)
CRR = Complete response rate
ORR = Objective response rate
R = Response (Objective or complete response)
HR = Hazard ratio
OR = Odds ratio
m = months
UV = Univariate
MV = Multivariate
NR = Non reported
*EASL criteria
**Non-R does not include stable disease
***RECIST 1.1 criteria
^0-25% reduction (17.7m); 0-25% increase (11.7m); ≥25% increase (8.9m).
Local ablation
Chemo-
embolization
Sorafenib
Other systemic 
therapies
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1st 
line 
2nd 
line 
Sorafenib Lenvatinib 
Advanced stage (BCLC C: Portal invasion and/or extrahepatic spread) 
Intermediate stage (BCLC B: Multinodular) progressing upon loco-regional therapies 
Regorafenib Cabozantinib Nivolumab 
OS HR=0.69 (vs Placebo) OS HR=0.92 (vs Sorafenib) 
OS HR=0.63 (vs Placebo) OS HR=0.76 (vs Placebo) ORR=18% (mRECIST) 
Child-Pugh A - ECOG PS ≤2 
*Higher benefit in HCV 
infection and lack of EHS 
Child-Pugh A - ECOG PS ≤1 
No invasion main portal vein 
PD 
Child-Pugh A - ECOG PS ≤1 
Tolerant to sorafenib (≈85%) 
Child-Pugh A - ECOG PS ≤1 
Child-Pugh A - ECOG PS ≤1 
*PDL1 IHC not a predictive 
biomarker 
Ramucirumab 
OS HR=0.71 (vs Placebo) 
Child-Pugh A - ECOG PS ≤1 
AFP ≥ 400ng/ml 
PD 
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